



**Clifford Andrew** (Male, born Sep. 10, 1946)



132 ST. ANDREWS ROAD  
SEVERNA PARK, MD 21146



4104047170 (Mobile)  
4109876789 (Home)  
4106475000 (Work)  
neuro1@jhmi.edu  
neuro1@verizon.net

*Note from Johns Hopkins Medicine*

This document contains information that was shared with Clifford Andrew. It may not contain the entire record from Johns Hopkins Medicine.

## Allergies

Not on file

## Current Medications

**ascorbic acid (VITAMIN C) 500 MG tablet**

Take 500 mg by mouth daily.

**aspirin 81 MG EC tablet**

Take 81 mg by mouth daily.

**atorvastatin (LIPITOR) 40 MG tablet (Started 3/1/2016)**

40 mg.

**FOLIC ACID ORAL**

Take 800 mcg by mouth daily.

**hydrochlorothiazide (MICROZIDE) 12.5 mg capsule**

Take 12.5 mg by mouth daily.

**losartan (COZAAR) 100 MG tablet (Started 5/12/2016)**

Take 0.5 tablets (50 mg total) by mouth daily.

**multivitamin capsule**

Take 1 capsule by mouth daily.

**niacin (VITAMIN B3) 500 MG tablet (Started 12/22/2014)**

Take 1 tablet (500 mg total) by mouth 2 (two) times daily with meals.  
3 refills left

**sildenafil (VIAGRA) 50 MG tablet (Started 5/12/2016)**

Take 1 tablet (50 mg total) by mouth daily as needed.  
5 refills left

**vitamin E 400 UNIT capsule**

Take 400 units by mouth daily.

## Active Problems

**Hyperlipidemia** (Noted 5/1/2008)

**Hypertension** (Noted 5/1/2008)

**Lyme disease, acute - probable 2014** (Noted 5/2/2014)

**Osteoarthritis of left knee** (Noted 11/12/2015)

**Posterior vitreous detachment of right eye** (Noted 2/19/2015)

## Immunizations

**Influenza, High dose, Seasonal** (Given 11/12/2015)

**Influenza, seasonal (Injectable)** (Given 2/9/2012, 11/1/2013, 10/8/2014)

**PNEUMOCOCCAL CONJUGATE 13-VALENT** (Given 11/12/2015)

**PNEUMOCOCCAL POLYSACCHARIDE** (Given 2/9/2012)

**Td (Unspecified Formulation)** (Given 10/14/2004)

**Tdap** (Given 5/8/2014)

## Results

**LIPID PANEL - Final result (05/12/2016 7:27 AM)**

| Component   | Value | Range       |
|---|-------|-------------|
| Cholesterol   | 165   | 0-200 mg/dL |
| Triglycerides   | 86    | 0-150 mg/dL |
| HDL Cholesterol   | 51    | >40 mg/dL   |
| LDL Calculated  | 97    | 0-130 mg/dL |
| Non-HDL Cholesterol, Calculated.  | 114   | mg/dL       |
| Comment: Target for Non-HDL Chol is 30 mg/dL higher than target LDL-Chol. |       |             |
| Total Chol/HDL Ratio  | 3.2   |             |

**PSA, TOTAL - Final result (05/12/2016 7:27 AM)**

| Component  | Value | Range         |
|--|-------|---------------|
| Prostate Spec Ag-TOSOH   | 6.1   | 0.0-4.0 mg/mL |
| Comment:<br>The presence of human anti-mouse antibodies (HAMA), which can result from mouse monoclonal antibodies used for diagnosis or therapy, or heterophile antibodies, may cause an interference in this assay. |       |               |

**HEMOGLOBIN A1C - Final result (05/12/2016 7:27 AM)**

| Component      | Value | Range     |
|----------------|-------|-----------|
| Hemoglobin A1C | 5.7   | 4.5-6.1 % |

**3-D RENDERING POSTPROCESS BODY - Final result (03/24/2016 8:45 AM)**

**Impressions**

**IMPRESSION:**

1. Renal cysts are noted bilaterally without evidence of renal mass.
2. Enlarged prostate gland with elevation of base of bladder by an enlarged prostate.
3. Multiple 3-D images are generated and enclosed with this report. No other findings of note are seen.

The 3-D reconstructions were performed on an independent 3-D workstation.

...: Created By CMURY1. Last update: Mar 26 2016 4:14P.

IMAGES AND INTERPRETATION PERSONALLY READ BY:

ELLIOT K FISHMAN MD

RESULT ELECTRONICALLY SIGNED

**Narrative**

Exam 1: CBJ 6070 - 3-D RENDERING POSTPROCESS BODY - Mar 24, 2016  
08:45 Acc#:15626469

**RESULT:**

**HISTORY:** The patient has hematuria and the study is done for evaluation.

**FINDINGS:**

On noncontrast scans:

- \* Liver and spleen are unremarkable.
- \* Cysts are present in the lateral aspect mid portion right kidney. No hydronephrosis is seen.

On arterial phase imaging:

- \* The liver and spleen are unremarkable.
- \* Pancreas appears normal.
- \* Kidneys function normally bilaterally with multiple right renal cysts.
- \* Atherosclerotic disease of aorta is defined.
- \* Prostate is enlarged.
- \* Good visualization of vascular map is noted.
- \* SMA and celiac axis are unremarkable with atherosclerotic changes of aorta noted.
- \* The patient has slight irregularity of left renal artery. Renal arteries bilaterally are otherwise unremarkable.
- \* Slight nodularity is present in both renal arteries consistent with what appears to be mild atherosclerotic change.

On venous phase:

- \* The kidneys enhance normally bilaterally.
- \* Several right renal cysts are defined.

#### Narrative

\* Good visualization with normal enhancement of the kidneys bilaterally is seen.

On delayed phase imaging:

- \* Good visualization of vascular map is defined.
- \* Renal pelves and collecting systems bilaterally are unremarkable.
- \* Elevation of base of bladder by enlarged prostate gland is seen.
- \* Multiple bilateral renal cysts are seen. No other findings of note are seen.

#### CT Abdomen Pelvis W/WO Contrast (CT ABDOMEN PELVIS W/WO CONTRAST) - Final result (03/24/2016 8:45 AM)

##### Impressions

---

###### IMPRESSION:

1. No CT explanation for the patient's symptoms. No solid renal mass. No evidence of a mass in the urinary tract. No hydronephrosis or nephrolithiasis.
2. Enlarged prostate with mild mass effect on the bladder neck.
3. Probable gallbladder adenomyomatosis, which can be confirmed with ultrasound.

..: Created By AOMBl. Last update: Mar 24 2016 9:17A.

ABISOLA ODUNBAKU MD

IMAGES AND INTERPRETATION PERSONALLY REVIEWED BY:

SHEILA SHETH MD

RESULT ELECTRONICALLY SIGNED

##### Narrative

---

Exam 1: CBJ 5044 - CT ABDOMEN PELVIS W/WO CONTRAST - Mar 24, 2016  
08:45 Acc#:15626468

RESULT: INDICATION: Painless gross hematuria.

COMPARISON: Renal ultrasound 12/27/2015

TECHNIQUE: CT abdomen and pelvis without and with intravenous contrast. Arterial, portal venous, and excretory phase images were obtained. Coronal and sagittal reformats.

###### FINDINGS:

###### LOWER CHEST:

The lung bases and visualized portions of the heart are unremarkable.

###### ABDOMEN/PELVIS:

Liver and pancreaticobiliary system: Minimal cholelithiasis without evidence of acute cholecystitis on CT. Focal gallbladder adenomyomatosis at the gallbladder fundus. Unremarkable liver and pancreas.

Adrenal glands and spleen: Multiple punctate calcified splenic granulomas. Unremarkable adrenal glands.

Genitourinary system: Symmetric renal enhancement. No hydronephrosis or nephrolithiasis. Simple right renal cyst, measuring up to 1.7 cm. 2.5 cm minimally complex cyst in the mid right kidney, containing a thin septation. Scattered additional subcentimeter hypodensities throughout bilateral kidneys, too small to characterize. No solid renal mass. Normal appearance of the urinary tract. The prostate is enlarged, measuring up to 6.3 cm in transverse dimension. Mild prostatic median lobe hypertrophy, which exerts mild mass effect on the bladder neck. No CT evidence of a bladder mass.

Gastrointestinal system: Normal appearance of the stomach, small bowel, and appendix. Interpositioning of the hepatic flexure between the right hemidiaphragm and the anterior aspect of the liver. Scattered colonic diverticula without evidence of acute diverticulitis. No free air free fluid.

Vasculature: Normal course and caliber of the abdominal aorta. Moderate atherosclerotic disease of the aorta and iliac arteries. Mild calcifications at the origins of the celiac and superior mesenteric arteries without significant stenosis. Mild calcifications of the proximal renal arteries without significant stenosis. Patent portal, superior mesenteric, and splenic veins. Patent hepatic and renal veins. Unremarkable IVC.

Lymph nodes, mesentery, and retroperitoneum: No enlarged lymph nodes in

**Narrative**

the abdomen or pelvis. Small fat-containing left inguinal hernia. Tiny fat-containing umbilical hernia.

**MUSCULOSKELETAL AND SOFT TISSUES:**

Mild degenerative changes of the spine. No suspicious osseous lesion.

**POC-CREATININE WITH EGFR, WHOLE BLOOD - Final result (03/24/2016 8:30 AM)**

| Component            | Value       | Range               |
|----------------------|-------------|---------------------|
| Creatinine, POC      | 0.85        | 0.60-1.30 mg/dL     |
| EGFR, POC            | >60         | >60 mL/min/1.73 sqm |
| Nova-Instrument Name | SS JHOC CT5 |                     |

**PROSTATE HEALTH INDEX (PHI) - Final result (02/10/2016 9:22 AM)**

| Component       | Value | Range         |
|-----------------|-------|---------------|
| PSA (Hybritech) | 5.1   | 0.0-4.0 ng/mL |

**Comment:**

The presence of human anti-mouse antibodies (HAMA), which can result from mouse monoclonal antibodies used for diagnosis or therapy, or heterophile antibodies, may cause an interference in this assay.

|             |      |   |
|-------------|------|---|
| PSA, % Free | 24.1 | % |
|-------------|------|---|

**Comment:**

In Men with total PSA concentrations between 4.0 and 10.0 ng/mL and a non-suspicious digital rectal examination, percent free (unbound) PSA may be used as an aid in distinguishing prostate cancer from benign conditions. In such patients, the probability of cancer is as follows:

| Cancer | %Free PSA | Probability of |
|--------|-----------|----------------|
| --     | 0 - 10%   | 56%            |
|        | 10 - 15%  | 28%            |
|        | 15 - 20%  | 20%            |
|        | 20 - 25%  | 16%            |
|        | > 25%     | 8%             |

The clinical utility of percent free PSA for total PSA concentrations outside the 4.0 - 10.0 ng/mL range has not been firmly established. For interpretation or questions, consult the following reference: Partin AW, . . . , Chan DW. Analysis of % Free PSA for Prostate Cancer Detection. Urology 1996;48(6A) 55-61.

|                             |      |  |
|-----------------------------|------|--|
| Prostate Health Index (phi) | 33.6 |  |
|-----------------------------|------|--|

**Comment:**

In men with total PSA concentrations between 4.0 and 10.0 ng/mL and a non-suspicious digital rectal examination, phi may be used as an aid in distinguishing prostate cancer from benign conditions.

| Cancer | phi Score | Probability of |
|--------|-----------|----------------|
|        | 0-26.9    | 9.8%           |
|        | 27.0-35.9 | 16.8%          |
|        | 36.0-54.9 | 33.3%          |
|        | >54.9     | 50.1%          |

The clinical utility of phi for total PSA concentrations outside the 4-10 ng/mL range has not been firmly established. For interpretation or questions,

| Component | Value  | Range |
|-----------|--|-------|
|           | consult the following reference:<br>Catalona WL, Partin AW, et al J Urol<br>2011;185:1650-5. |       |

**UROLOGY QUINOLONE RESISTANCE SCREEN - Final result (02/10/2016 8:57 AM)**

| Component           | Value   | Range |
|---------------------|---|-------|
| Urology FLQR Screen | Negative for fluoroquinolone resistant Gram Negative Rods |       |

**URINE LIQUID BASED, CYTOPATH - Final result (02/10/2016)**

| Component | Value | Range |
|-----------|-------|-------|
|-----------|-------|-------|

Cytopathology Report

THE Patient: ANDREW MD,CLIFFORD Path# C16-2982

JOHNS HOPKINS HOSPITAL JHH MR # 5-163-62-84 Accessioned 02/10/2016

CYTOPATHOLOGY Birthdate: 09/10/1946 (Age 69) Loc: 204

600 N. Wolfe Street Gender: M Spec. Taken 02/10/2016

Baltimore, Md. 21287-8048 JHH Physician: HERBERT BALLENTINE CARTER, M.D.

SPECIMEN INFORMATION =====

Resident Pathologist: DEREK ALLISON, M.D.

Specimen 1 URINE VOIDED, LIQUID BASED  
Amount: 50 cc Fresh Clear YELLOW  
Technician: DFR  
1 Vial

INTERPRETATION AND DIAGNOSIS: (ljz) 02/12/2016 @ 02:26 pm

1) URINE VOIDED, LIQUID BASED:

FINAL DIAGNOSIS: ATYPICAL UROTHELIAL CELLS OF UNCERTAIN SIGNIFICANCE.

URINE CHARACTERISTICS: RED BLOOD CELLS.

ADEQUACY: SATISFACTORY FOR EVALUATION.

SYED Z. ALI, M.D. SZA\*

\*Electronic signature (02/12/2016 @ 02:48 pm) by which I attest that the above diagnosis is based upon my personal examination of the slides (and / or other material indicated in the diagnosis), and that I have reviewed and approved this report.

(End of Report) printed 02/12/2016 14:59

Reported by:  
The Johns Hopkins Hospital, Cytopathology  
600 N. Wolfe St., Baltimore, MD 21287  
Tel: 410-955-3520

Final Report Signed on 02/12/2016 at 02:48 pm

**COMPREHENSIVE METABOLIC PANEL - Final result (12/29/2015 8:00 AM)**

| Component                  | Value | Range               |
|----------------------------|-------|---------------------|
| Sodium                     | 141   | 135-148 meq/L       |
| Potassium                  | 4.8   | 3.5-5.1 meq/L       |
| Chloride                   | 101   | 96-109 meq/L        |
| Carbon Dioxide             | 29    | 21-31 meq/L         |
| Urea Nitrogen              | 16    | 7-22 mg/dL          |
| Creatinine,Serum           | 1.0   | 0.6-1.3 mg/dL       |
| Est GFR Afr-Am(MDRD Eqn)   | >60   | >60 mL/min/1.73 sqm |
| Est GFR NonAfrAm(MDRD Eqn) | >60   | >60 mL/min/1.73 sqm |
| Glucose                    | 109   | 60-99 mg/dL         |

Comment:  
Interpretation

| Component              | Value  | Range          |
|------------------------|--|----------------|
|                        | Fasting glucose 100-125 mg/dL: Impaired                              |                |
|                        | Fasting glucose >=126 mg/dL: Diagnostic for diabetes                 |                |
|                        | Random glucose >=200 mg/dL: Diagnostic for diabetes when symptomatic |                |
| Calcium                | 9.8  | 8.4-10.5 mg/dL |
| Total Protein          | 7.5  | 6.0-8.2 g/dL   |
| Albumin                | 4.5  | 3.5-5.3 g/dL   |
| Bilirubin, Total       | 0.9  | 0.0-1.2 mg/dL  |
| Alkaline Phosphatase   | 51   | 30-120 U/L     |
| Aspartate Amino Trans  | 25   | 0-37 U/L       |
| Alanine Amino Trans    | 25   | 0-40 U/L       |
| Anion Gap              | 11   | 7-16 meq/L     |
| BUN / Creatinine Ratio | 16   |                |
| AST/ALT Ratio          | 1.0  |                |

**LIPID PANEL - Final result (12/29/2015 8:00 AM)**

| Component                        | Value   | Range       |
|----------------------------------|---|-------------|
| Cholesterol                      | 205   | 0-200 mg/dL |
| Triglycerides                    | 148   | 0-150 mg/dL |
| HDL Cholesterol                  | 53  | >40 mg/dL   |
| LDL Calculated                   | 122   | 0-130 mg/dL |
| Non-HDL Cholesterol, Calculated. | 152   | mg/dL       |
|                                  | Comment: Target for Non-HDL Chol is 30 mg/dL higher than target LDL-Chol. |             |
| Total Chol/HDL Ratio             | 3.9   |             |

**HEMOGLOBIN A1C - Final result (12/29/2015 8:00 AM)**

| Component      | Value | Range     |
|----------------|-------|-----------|
| Hemoglobin A1C | 6.1   | 4.5-6.1 % |

**PSA, TOTAL - Final result (12/29/2015 8:00 AM)**

| Component              | Value  | Range         |
|------------------------|--|---------------|
| Prostate Spec Ag-TOSOH | 5.1  | 0.0-4.0 ng/mL |
|                        | Comment:<br>The presence of human anti-mouse antibodies (HAMA), which can result from mouse monoclonal antibodies used for diagnosis or therapy, or heterophile antibodies, may cause an interference in this assay. |               |

**COMPLETE BLOOD COUNT (CBC) WITHOUT DIFFERENTIAL - Final result (12/29/2015 8:00 AM)**

| Component               | Value | Range              |
|-------------------------|-------|--------------------|
| White Blood Cell Count  | 9.58  | 4.50-11.00 K/cu mm |
| Red Blood Cell Count    | 4.83  | 4.50-5.90 M/cu mm  |
| Hemoglobin              | 14.0  | 13.9-16.3 g/dL     |
| Hematocrit              | 41.4  | 41.0-53.0 %        |
| Mean Corpuscular Volume | 85.7  | 80.0-100.0 fL      |
| Mean Corpus Hgb         | 29.0  | 26.0-34.0 pg       |
| Mean Corpus Hgb Conc    | 33.8  | 31.0-37.0 g/dL     |
| RBC Distribution Width  | 12.4  | 11.5-14.5 %        |
| Platelet Count          | 277   | 150-350 K/cu mm    |
| Mean Platelet Volume    | 8.8   | 9.2-12.7 fL        |
| Nucleated RBC Number    | 0.00  | 0.00-0.01 K/cu mm  |

**US Kidney Bladder (US KIDNEY BLADDER) - Final result (12/27/2015 1:05 PM)**

**Impressions**

**IMPRESSION:**

- Two cysts described above in the right kidney.
- Prominent prostate gland indents the base of the bladder.
- If hematuria persists or if clinically indicated CT might be a further consideration.

...: Created By BBERN2. Last update: Dec 27 2015 1:08P.

IMAGES AND INTERPRETATION PERSONALLY READ BY:

BRUCE P BERLANSTEIN MD

RESULT ELECTRONICALLY SIGNED

**Narrative**

Exam 1: UAE 2708 - US KIDNEY BLADDER - Dec 27, 2015 13:05  
 Acc#:15498857

RESULT: Indication: Painless hematuria.

Technique: Real-time ultrasound performed.

**Findings:**

The right kidney measures 11.4 cm. Vascular flow is noted in the right kidney. A small septated cyst is seen the upper pole the right kidney measuring 1.4 x 1.1 x 1 cm. In the mid right kidney there is a bilobed cyst that measures 2.6 x 2 x 1.6 cm. No renal obstruction noted.

The left kidney measures 12.5 cm. No evidence of renal obstruction. Vascular flow seen the left kidney.

The prostate gland appears prominent measuring 68.5 mL. Prostate gland indents the base of the bladder and there is a calcification the prostate gland.

**URINALYSIS - Final result (12/27/2015 11:24 AM)**

| Component   | Value    | Range            |
|---|----------|------------------|
| Color, Urine  | Yellow   |                  |
| Appearance, Urine   | Clear    |                  |
| Specific Gravity, Urine   | 1.015    | 1.003-1.030      |
| Urine pH  | 8.0      | 4.6-8.0          |
| Protein Semiquant, UA   | Negative | Negative         |
| Glucose, Urine, Semiquant   | Negative | Negative mg/dL   |
| Ketones, Urine, Qualitative   | Negative | Negative         |
| Bilirubin, Urine, Qualitative   | Negative | Negative         |
| Blood, Urine  | Moderate | Negative         |
| Nitrite, Urine  | Negative | Negative         |
| Leukocyte Esterase, Urine   | Negative | Negative         |
| Urobilinogen, Urine   | 0.2      | 0.2-1.0 mg/dL    |
| White Blood Cells, Urine  | 2        | 0-5 /[HPF]       |
| White Blood Cells, UA   | 9        | 0-27 /uL         |
| Red Blood Cells, Urine  | 10       | 0-5 /[HPF]       |
| Red Blood Cells, UA   | 53       | 0-27 /uL         |
| Hyaline Casts, Urine  | 1        | 0-1 /[LPF]       |
| Granular Casts, Urine   | 0        | None seen /[LPF] |
| Epithelial Cells, Urine   | <1       | /[HPF]           |
| <p><b>Comment:</b><br/>           Any number of squamous epithelial cells is normal. The presence of either renal or transitional epithelial cells is abnormal.</p> |          |                  |
| Bacteria, Urine   | Rare     | None-few /[HPF]  |
| Mucus Threads, Urine  | Rare     | None-few /[LPF]  |
| Crystals  | None     | None-few /[HPF]  |

**CHLAMYDIA / N. GONORRHOEAE COMBO NAT, URINE - Final result (12/27/2015 11:24 AM)**

| Component                    | Value  | Range    |
|------------------------------|--|----------|
| Chlamydia Trachomatis, Urine | Negative<br>Comment: Negative for Chlamydia trachomatis by nucleic acid detection. | Negative |
| N.Gonorrhoeae, Urine         | Negative<br>Comment: Negative for Neisseria gonorrhoeae by nucleic acid detection. | Negative |

**XR KNEE RT 1 OR 2 VWS - Final result (08/20/2015 8:26 AM)**

**Impressions**

**IMPRESSION:**

**Right knee:**

Moderate medial compartment narrowing with slight varus deformity, not significantly changed since 4/5/2012. Small marginal osteophytes tibial plateau.  
 Small region of sclerosis measuring 9 mm in the posterior lateral femoral condyle, likely bone island.  
 Mild patellofemoral arthritis with tiny marginal patellar osteophytes.  
 Small joint effusion.  
 Cortical irregularity lateral fibular head likely from prior trauma.  
 Tiny calcifications in the region of the intercondylar notch may represent small intra-articular bodies.

**Left knee:**

Marked medial compartment narrowing, with slight varus deformity.  
 Osteophytes at tibial spines.

**Impressions**

Small intra-articular loose body.  
Mild patellofemoral arthritis with tiny marginal patellar osteophytes.

..: Created By JWN16. Last update: Aug 20 2015 9:39A.

IMAGES AND INTERPRETATION PERSONALLY READ BY:

NEIL KUMAR MD

RESULT ELECTRONICALLY SIGNED

**Narrative**

Exam 1: GDH 1710 - XR KNEE RT 1 OR 2 VWS - Aug 20, 2015 08:26  
Acc#:15011384

Exam 2: GDH 1727 - XR KNEE BILATERAL 3 VWS - Aug 20, 2015 08:26  
Acc#:15011385

RESULT: Exam: Bilateral knees, 4 views.

Clinical Information: Right knee pain. History of osteoarthritis and traumatic prepatellar bursitis.

Comparison: Bilateral knee radiographs 4/5/2012.

**XR KNEE BIL 3 VWS (XR KNEE BILATERAL 3 VWS) - Final result (08/20/2015 8:26 AM)**

**Impressions**

**IMPRESSION:**

Right knee:

Moderate medial compartment narrowing with slight varus deformity, not significantly changed since 4/5/2012. Small marginal osteophytes tibial plateau.

Small region of sclerosis measuring 9 mm in the posterior lateral femoral condyle, likely bone island.

Mild patellofemoral arthritis with tiny marginal patellar osteophytes.

Small joint effusion.

Cortical irregularity lateral fibular head likely from prior trauma.

Tiny calcifications in the region of the intercondylar notch may represent small intra-articular bodies.

Left knee:

Marked medial compartment narrowing, with slight varus deformity.

Osteophytes at tibial spines.

Small intra-articular loose body.

Mild patellofemoral arthritis with tiny marginal patellar osteophytes.

..: Created By JWN16. Last update: Aug 20 2015 9:39A.

IMAGES AND INTERPRETATION PERSONALLY READ BY:

NEIL KUMAR MD

RESULT ELECTRONICALLY SIGNED

**Narrative**

Exam 1: GDH 1710 - XR KNEE RT 1 OR 2 VWS - Aug 20, 2015 08:26  
Acc#:15011384

Exam 2: GDH 1727 - XR KNEE BILATERAL 3 VWS - Aug 20, 2015 08:26  
Acc#:15011385

RESULT: Exam: Bilateral knees, 4 views.

Clinical Information: Right knee pain. History of osteoarthritis and traumatic prepatellar bursitis.

Comparison: Bilateral knee radiographs 4/5/2012.

**ADULT SLEEP STUDY (PSG) - DIAGNOSIS AND REFERRAL (NON-SLEEP PROVIDERS) (ADULT SLEEP STUDY-DIAGNOSIS & REFERRAL FOR THERAPY(NON-SLEEP PROVIDERS ONLY)) - Final result (05/27/2015 3:41 PM)**

**COMPREHENSIVE METABOLIC PANEL - Final result (02/05/2015 9:03 AM)**

| Component | Value | Range         |
|-----------|-------|---------------|
| Sodium    | 138   | 135-148 meq/L |



| Component                | Value | Range         |
|--------------------------|-------|---------------|
| Potassium                | 4.5   | 3.5-5.1 meq/L |
| Chloride                 | 98    | 96-109 meq/L  |
| Carbon Dioxide           | 28    | 21-31 meq/L   |
| Urea Nitrogen            | 16    | 7-22 mg/dL    |
| Creatinine,Serum         | 1.1   | 0.6-1.3 mg/dL |
| Est GFR Afr-Am(MDRD Eqn) | >60   | mL/min/A      |

**Comment:**

Estimated GFR is calculated from serum creatinine using the Modification of Diet in Renal Disease (MDRD) equation in patients 18 years or older.  
Reference Range: >60 mL/min/A, (A=1.73 sq m).

|                            |     |          |
|----------------------------|-----|----------|
| Est GFR NonAfrAm(MDRD Eqn) | >60 | mL/min/A |
|----------------------------|-----|----------|

**Comment:**

Estimated GFR is calculated from serum creatinine using the Modification of Diet in Renal Disease (MDRD) equation in patients 18 years or older.  
Reference Range: >60 mL/min/A, (A=1.73 sq m).

|         |     |             |
|---------|-----|-------------|
| Glucose | 112 | 60-99 mg/dL |
|---------|-----|-------------|

**Comment:**  
Interpretation  
Fasting glucose 100-125 mg/dL: Impaired  
Fasting glucose ≥ 126 mg/dL: Diagnostic for diabetes  
Random glucose ≥ 200 mg/dL: Diagnostic for diabetes when symptomatic

|                        |      |                |
|------------------------|------|----------------|
| Calcium                | 10.1 | 8.4-10.5 mg/dL |
| Total Protein          | 7.3  | 6.0-8.2 g/dL   |
| Albumin                | 4.5  | 3.5-5.3 g/dL   |
| Bilirubin,Total        | 0.8  | 0.0-1.2 mg/dL  |
| Alkaline Phosphatase   | 50   | 30-120 U/L     |
| Aspartate Amino Trans  | 21   | 0-37 U/L       |
| Alanine Amino Trans    | 17   | 0-40 U/L       |
| Anion Gap              | 12   | 7-16 meq/L     |
| BUN / Creatinine Ratio | 15   |                |
| AST/ALT Ratio          | 1.2  |                |

**HEMOGLOBIN A1C - Final result (02/05/2015 9:03 AM)**

| Component      | Value | Range     |
|----------------|-------|-----------|
| Hemoglobin A1C | 5.8   | 4.5-6.1 % |

**LIPID PANEL - Edited Result - FINAL (02/05/2015 9:03 AM)**

| Component            | Value | Range       |
|----------------------|-------|-------------|
| Cholesterol          | 152   | 0-200 mg/dL |
| Triglycerides        | 92    | 0-150 mg/dL |
| HDL Cholesterol      | 63    | mg/dL       |
| LDL Calculated       | 71    | mg/dL       |
| Total Chol/HDL Ratio | 2.4   |             |

**Comment:**

Cholesterol reference note.

Reference Range:

Cholesterol

Desirable < 200 mg/dL

Borderline High 200-230 mg/dL

High > 240 mg/dL

Triglyceride

Normal < 150 mg/dL

Borderline High 150-199 mg/dL

High 200-499 mg/dL

Very High > 500 mg/dL

HDL Cholesterol

Undesirable < 40 mg/dL

Desirable > 60 mg/dL

LDL Cholesterol

Optimal < 100 mg/dL

Above Optimal 100-129 mg/dL

Borderline High 130-159 mg/dL

High 160-189 mg/dL

Very High > 190 mg/dL

Categories of RISK that modify LDL

Cholesterol Goals

CHD and CHR risk equivalents < 100 mg/dL

Multiple (2+) risk factors <

| Component | Value            | Range |
|-----------|------------------|-------|
|           | 130 mg/dL        |       |
|           | 0-1 risk factors | <     |
|           | 160 mg/dL        |       |

**COMPLETE BLOOD COUNT (CBC) WITHOUT DIFFERENTIAL - Final result (02/05/2015 9:03 AM)**

| Component               | Value | Range              |
|-------------------------|-------|--------------------|
| White Blood Cell Count  | 8.49  | 4.50-11.00 K/cu mm |
| Red Blood Cell Count    | 4.59  | 4.50-5.90 M/cu mm  |
| Hemoglobin              | 13.6  | 13.9-16.3 g/dL     |
| Hematocrit              | 40.0  | 41.0-53.0 %        |
| Mean Corpuscular Volume | 87.1  | 80.0-100.0 fL      |
| Mean Corpus Hgb         | 29.6  | 26.0-34.0 pg       |
| Mean Corpus Hgb Conc    | 34.0  | 31.0-37.0 g/dL     |
| RBC Distribution Width  | 12.5  | 11.5-14.5 %        |
| Platelet Count          | 245   | 150-350 K/cu mm    |
| Mean Platelet Volume    | 9.2   | 9.2-12.7 fL        |
| Nucleated RBC Number    | 0.00  | 0.00-0.01 K/cu mm  |

**COMPREHENSIVE METABOLIC PANEL - Final result (05/01/2014 8:54 AM)**

| Component                | Value | Range         |
|--------------------------|-------|---------------|
| Sodium                   | 142   | 135-148 mEq/L |
| Potassium                | 4.7   | 3.5-5.1 mEq/L |
| Chloride                 | 102   | 96-109 mEq/L  |
| Carbon Dioxide           | 30    | 21-31 mEq/L   |
| Urea Nitrogen            | 14    | 7-22 mg/dL    |
| Creatinine,Serum         | 1.0   | 0.6-1.3 mg/dL |
| Est GFR Afr-Am(MDRD Eqn) | >60   | mL/min/A      |

**Comment:**

Estimated GFR is calculated from serum creatinine using the Modification of Diet in Renal Disease (MDRD) equation in patients 18 years or older.  
Reference Range: >60 mL/min/A, (A=1.73 sq m).

|                            |   |          |
|----------------------------|---|----------|
| Est GFR NonAfrAm(MDRD Eqn) | >60   | mL/min/A |
|                            | <b>Comment:</b>   |          |
|                            | Estimated GFR is calculated from serum creatinine using the Modification of Diet in Renal Disease (MDRD) equation in patients 18 years or older.<br>Reference Range: >60 mL/min/A, (A=1.73 sq m). |          |

|         |   |             |
|---------|---|-------------|
| Glucose | 109   | 60-99 mg/dL |
|         | <b>Comment:</b>   |             |
|         | Interpretation<br>Fasting glucose 100-125 mg/dL: Impaired<br>Fasting glucose>=126 mg/dL: Diagnostic for diabetes<br>Random glucose>=200 mg/dL: Diagnostic for diabetes when symptomatic |             |

|                        |      |                |
|------------------------|------|----------------|
| Calcium                | 10.5 | 8.4-10.5 mg/dL |
| Total Protein          | 7.3  | 6.0-8.2 g/dL   |
| Albumin                | 4.7  | 3.5-5.3 g/dL   |
| Bilirubin,Total        | 1.3  | 0.1-1.2 mg/dL  |
| Alkaline Phosphatase   | 51   | 30-120 U/L     |
| Aspartate Amino Trans  | 32   | 0-37 U/L       |
| Alanine Amino Trans    | 31   | 0-40 U/L       |
| Anion Gap              | 10   | 7-16 mEq/L     |
| BUN / Creatinine Ratio | 14   |                |
| AST/ALT Ratio          | 1.0  |                |

**LIPID PANEL - Final result (05/01/2014 8:54 AM)**

| Component            | Value | Range       |
|----------------------|-------|-------------|
| Cholesterol          | 160   | 0-200 mg/dL |
| Triglycerides        | 61    | 0-150 mg/dL |
| HDL Cholesterol      | 65    | mg/dL       |
| LDL Calculated       | 83    | mg/dL       |
| Total Chol/HDL Ratio | 2.5   |             |

**Comment:**

Cholesterol reference note.

Reference Range:

Cholesterol

Desirable < 200 mg/dL

Borderline High 200-230 mg/dL

High > 240 mg/dL

Triglyceride

| Component  | Value                        | Range         |
|--|------------------------------|---------------|
|  | Normal                       | < 150 mg/dL   |
|  | Borderline High              | 150-199 mg/dL |
|  | High                         | 200-499 mg/dL |
|  | Very High                    | > 500 mg/dL   |
| HDL Cholesterol                                      |                              |               |
|  | Undesirable                  | < 40 mg/dL    |
|  | Desirable                    | > 60 mg/dL    |
| LDL Cholesterol                                      |                              |               |
|  | Optimal                      | < 100 mg/dL   |
|  | Above Optimal                | 100-129 mg/dL |
|  | Borderline High              | 130-159 mg/dL |
|  | High                         | 160-189 mg/dL |
|  | Very High                    | > 190 mg/dL   |
| Categories of RISK that modify LDL Cholesterol Goals |                              |               |
|  | CHD and CHR risk equivalents | < 100 mg/dL   |
|  | Multiple (2+) risk factors   | < 130 mg/dL   |
|  | 0-1 risk factors             | < 160 mg/dL   |

**COMPLETE BLOOD COUNT (CBC) WITHOUT DIFFERENTIAL - Final result (12/05/2013 9:01 AM)**

| Component               | Value | Range              |
|-------------------------|-------|--------------------|
| Red Blood Cell Count    | 4.77  | 4.50-5.90 M/cu mm  |
| Hemoglobin              | 13.7  | 13.9-16.3 g/dL     |
| Hematocrit              | 40.9  | 41.0-53.0 %        |
| Mean Corpuscular Volume | 85.7  | 80.0-100.0 fL      |
| Mean Corpus Hgb         | 28.7  | 26.0-34.0 pg       |
| Mean Corpus Hgb Conc    | 33.5  | 31.0-37.0 g/dL     |
| RBC Distribution Width  | 12.5  | 11.5-14.5 %        |
| Platelet Count          | 263   | 150-350 K/cu mm    |
| Mean Platelet Volume    | 9.5   | 9.2-12.7 fL        |
| White Blood Cell Count  | 6.64  | 4.50-11.00 K/cu mm |
| Nucleated RBC Number    | 0.00  | 0.00-0.01 K/cu mm  |

**HEMOGLOBIN A1C - Final result (12/05/2013 9:01 AM)**

| Component      | Value | Range     |
|----------------|-------|-----------|
| Hemoglobin A1C | 6.0   | 4.5-6.1 % |

**COMPREHENSIVE METABOLIC PANEL - Final result (12/05/2013 9:01 AM)**

| Component                | Value | Range         |
|--------------------------|-------|---------------|
| Sodium                   | 140   | 135-148 mEq/L |
| Potassium                | 4.6   | 3.5-5.1 mEq/L |
| Chloride                 | 102   | 96-109 mEq/L  |
| Carbon Dioxide           | 28    | 21-31 mEq/L   |
| Urea Nitrogen            | 21    | 7-22 mg/dL    |
| Creatinine,Serum         | 1.1   | 0.6-1.3 mg/dL |
| Est GFR Afr-Am(MDRD Eqn) | >60   | mL/min/A      |

**Comment:**

Estimated GFR is calculated from serum creatinine using the Modification of Diet in Renal Disease (MDRD) equation in patients 18 years or older.  
Reference Range: >60 mL/min/A, (A=1.73 sq m).

|   |     |          |
|---|-----|----------|
| Est GFR NonAfrAm(MDRD Eqn)  | >60 | mL/min/A |
| <b>Comment:</b>   |     |          |
| Estimated GFR is calculated from serum creatinine using the Modification of Diet in Renal Disease (MDRD) equation in patients 18 years or older.<br>Reference Range: >60 mL/min/A, (A=1.73 sq m). |     |          |

|   |     |             |
|---|-----|-------------|
| Glucose   | 106 | 60-99 mg/dL |
| <b>Comment:</b>   |     |             |
| Interpretation<br>Fasting glucose 100-125 mg/dL: Impaired<br>Fasting glucose ≥ 126 mg/dL: Diagnostic for diabetes<br>Random glucose ≥ 200 mg/dL: Diagnostic for diabetes when symptomatic |     |             |

|                      |     |                |
|----------------------|-----|----------------|
| Calcium              | 9.8 | 8.4-10.5 mg/dL |
| Total Protein        | 7.0 | 6.0-8.2 g/dL   |
| Albumin              | 4.4 | 3.5-5.3 g/dL   |
| Bilirubin,Total      | 0.4 | 0.1-1.2 mg/dL  |
| Alkaline Phosphatase | 40  | 30-120 U/L     |

| Component              | Value | Range      |
|------------------------|-------|------------|
| Aspartate Amino Trans  | 29    | 0-37 U/L   |
| Alanine Amino Trans    | 29    | 0-40 U/L   |
| Anion Gap              | 10    | 7-16 mEq/L |
| BUN / Creatinine Ratio | 19    |            |
| AST/ALT Ratio          | 1.0   |            |

**LIPID PANEL - Final result (12/05/2013 9:01 AM)**

| Component            | Value | Range       |
|----------------------|-------|-------------|
| Cholesterol          | 187   | 0-200 mg/dL |
| Triglycerides        | 109   | 0-150 mg/dL |
| HDL Cholesterol      | 52    | mg/dL       |
| LDL Calculated       | 113   | mg/dL       |
| Total Chol/HDL Ratio | 3.6   |             |

**Comment:**

Cholesterol reference note.

Reference Range:

Cholesterol

|                 |         |       |
|-----------------|---------|-------|
| Desirable       | < 200   | mg/dL |
| Borderline High | 200-230 | mg/dL |
| High            | > 240   | mg/dL |

Triglyceride

|                 |         |       |
|-----------------|---------|-------|
| Normal          | < 150   | mg/dL |
| Borderline High | 150-199 | mg/dL |
| High            | 200-499 | mg/dL |
| Very High       | > 500   | mg/dL |

HDL Cholesterol

|             |      |       |
|-------------|------|-------|
| Undesirable | < 40 | mg/dL |
| Desirable   | > 60 | mg/dL |

LDL Cholesterol

|                 |         |       |
|-----------------|---------|-------|
| Optimal         | < 100   | mg/dL |
| Above Optimal   | 100-129 | mg/dL |
| Borderline High | 130-159 | mg/dL |
| High            | 160-189 | mg/dL |
| Very High       | > 190   | mg/dL |

Categories of RISK that modify LDL

Cholesterol Goals

|                              |       |       |
|------------------------------|-------|-------|
| CHD and CHR risk equivalents | < 100 | mg/dL |
| Multiple (2+) risk factors   | < 130 | mg/dL |
| 0-1 risk factors             | < 160 | mg/dL |

**VITAMIN D 1,25 DIHYDROXY - Final result (12/05/2013 9:01 AM)**

| Component                  | Value     | Range |
|----------------------------|-----------|-------|
| Vitamin D (1,25-Dihydroxy) | SEE BELOW |       |

**Comment:**

VITAMIN D,1,25 (OH)2,TOTAL

45 18-72

VITAMIN D3, 1,25 (OH)2

45

VITAMIN D2, 1,25 (OH)2

<8

Vitamin D3, 1,25(OH)2 indicates both endogenous

production and supplementation. Vitamin D2, 1,25(OH)2

is an indicator of exogenous sources, such as diet or

supplementation. Interpretation and therapy are based

on measurement of Vitamin D,1,25(OH)2, Total.

This test was developed and its performance characteristics have been determined by Quest

Diagnostics Nichols Institute, Chantilly, VA. Performance characteristics refer to the

analytical performance of the test.

Test Performed by Quest, Chantilly,

Quest Diagnostics Nichols Institute,

14225 Newbrook Drive, Chantilly, VA 20151

Kenneth Sisco, M.D., Ph.D., Director of

Laboratories

(703) 802-6900, CLIA 49D0221801

**COMPREHENSIVE METABOLIC PANEL - Final result (01/17/2013 8:42 AM)**

| Component | Value | Range         |
|-----------|-------|---------------|
| Sodium    | 141   | 135-148 mEq/L |
| K-Serum   | 4.6   | 3.5-5.1 mEq/L |
| Chloride  | 100   | 96-109 mEq/L  |

| Component                  | Value   | Range          |
|----------------------------|---|----------------|
| CO2.                       | 30  | 21-31 mEq/L    |
| Glucose                    | 113   | 60-99 mg/dL    |
|                            | Comment:<br>Glucose values of 100-125 mg/dL indicate impaired fasting glucose.  |                |
| Urea-Nitrogen              | 18  | 7-22 mg/dL     |
| Creatinine, Serum.         | 1.0   | 0.6-1.3 mg/dL  |
| Calcium                    | 9.8   | 8.4-10.5 mg/dL |
| Total Protein              | 7.1   | 6.0-8.2 g/dL   |
| Albumin                    | 4.5   | 3.5-5.3 g/dL   |
| Total Bilirubin.           | 0.5   | 0.1-1.2 mg/dL  |
| Alkaline Phosphatase       | 41  | 30-120 U/L     |
| Aspartate Amino Tran       | 19  | 0-37 U/L       |
| Alanine Amino Transf       | 16  | 0-40 U/L       |
| Anion Gap                  | 11  | 7-16 mEq/L     |
| SUN/Creatinine Ratio       | 18  |                |
| AST/ALT Ratio              | 1.2   |                |
| Est GFR Afr-Am(MDRD Eqn)   | >60   | mL/min/A       |
|                            | Comment:<br>Estimated GFR is calculated from serum creatinine using the Modification of Diet in Renal Disease (MDRD) equation in patients 18 years or older.<br>Reference Range: >60 mL/min/A, (A=1.73 sq m). |                |
| Est GFR NonAfrAm(MDRD Eqn) | >60   | mL/min/A       |
|                            | Comment:<br>Estimated GFR is calculated from serum creatinine using the Modification of Diet in Renal Disease (MDRD) equation in patients 18 years or older.<br>Reference Range: >60 mL/min/A, (A=1.73 sq m). |                |

#### Narrative

Johns Hopkins Medical Labs  
 Zayed B-1065  
 600 North Wolfe Street  
 Baltimore, MD. 21287

#### VITAMIN D 1,25 DIHYDROXY - Final result (01/17/2013 8:42 AM)

| Component            | Value   | Range |
|----------------------|---|-------|
| Vitamin D (1,25-Dihy | SEE BELOW   |       |
|                      | Comment:<br>TESTS-----RESULTS-----FLAG-<br>-----REF RANGE-----UNITS<br>VITAMIN D,1,25 (OH)2,TOTAL<br>59 18-72<br>VITAMIN D3, 1,25 (OH)2 59<br>VITAMIN D2, 1,25 (OH)2 <8<br>Vitamin D3, 1,25(OH)2 indicates both endogenous production and supplementation. Vitamin D2, 1,25(OH)2 is an indicator of exogenous sources, such as diet or supplementation. Interpretation and therapy are based on measurement of Vitamin D,1,25(OH)2, Total. This test was developed and its performance characteristics have been determined by Quest Diagnostics Nichols Institute, Chantilly, VA. Performance characteristics refer to the analytical performance of the test. Test Performed by Quest, Chantilly, Quest Diagnostics Nichols Institute, 14225 Newbrook Drive, Chantilly, VA 20151 Kenneth Sisco, M.D., Ph.D., Director of Laboratories (703) 802-6900, CLIA 49D0221801 |       |

#### Narrative

QUEST, CHANTILLY,  
 Quest Diagnostics Nichols Institute,  
 14225 Newbrook Drive, Chantilly, VA 20151  
 Kenneth Sisco, M.D., Ph.D., Director of Laboratories  
 (703) 802-6900, CLIA 49D0221801

**LIPID PANEL - Final result (01/17/2013 8:42 AM)**

| Component            | Value | Range       |
|----------------------|-------|-------------|
| Cholesterol          | 177   | 0-200 mg/dL |
| Triglycerides        | 135   | 0-150 mg/dL |
| HDL Cholesterol.     | 52    | mg/dL       |
| LDL (Calculated).    | 98    | mg/dL       |
| Total Chol/HDL Ratio | 3.4   | Ratio       |

**Comment:**

Cholesterol reference note.

Reference Range:

Cholesterol

Desirable < 200 mg/dL

Borderline High 200-230 mg/dL

High > 240 mg/dL

Triglyceride

Normal < 150 mg/dL

Borderline High 150-199 mg/dL

High 200-499 mg/dL

Very High > 500 mg/dL

HDL Cholesterol

Undesirable < 40 mg/dL

Desirable > 60 mg/dL

LDL Cholesterol

Optimal < 100 mg/dL

Above Optimal 100-129 mg/dL

Borderline High 130-159 mg/dL

High 160-189 mg/dL

Very High > 190 mg/dL

Categories of RISK that modify LDL

Cholesterol Goals

CHD and CHR risk equivalents < 100 mg/dL

Multiple (2+) risk factors < 130 mg/dL

0-1 risk factors < 160 mg/dL

**Narrative**

Johns Hopkins Medical Labs  
Zayed B-1065  
600 North Wolfe Street  
Baltimore, MD. 21287

**COMPLETE BLOOD COUNT (CBC) WITHOUT DIFFERENTIAL (COMPLETE BLOOD COUNT (CBC)) - Final result (12/27/2012 9:49 AM)**

| Component               | Value | Range             |
|-------------------------|-------|-------------------|
| White Blood Cell Count  | 6870  | 4500-11000 /cu mm |
| Red Blood Cell Count    | 5.06  | 4.50-5.90 M/cu mm |
| Hemoglobin              | 14.8  | 13.9-16.3 g/dL    |
| Hematocrit              | 42.2  | 41.0-53.0 %       |
| Mean Corpuscular Volume | 83.4  | 80.0-100.0 fL     |
| Mean Corpus HgB         | 29.2  | 26.0-34.0 pg      |
| Mean Corpus HgB Conc    | 35.1  | 31.0-37.0 g/dL    |
| RBC Distribution Width  | 13.0  | 11.5-14.5 %       |
| Platelet Count          | 273   | 150-350 K/cu mm   |
| Mean Platelet Volume    | 10.2  | 9.2-12.7 fL       |
| Nucleated RBC Number    | 0     | 0-12 /cu mm       |

**Narrative**

Johns Hopkins Medical Labs  
Zayed B-1065  
600 North Wolfe Street  
Baltimore, MD. 21287

**COMPREHENSIVE METABOLIC PANEL - Final result (12/27/2012 9:49 AM)**

| Component | Value | Range         |
|-----------|-------|---------------|
| Sodium    | 144   | 135-148 mEq/L |
| K-Serum   | 4.5   | 3.5-5.1 mEq/L |
| Chloride  | 100   | 96-109 mEq/L  |
| CO2.      | 30    | 21-31 mEq/L   |
| Glucose   | 105   | 60-99 mg/dL   |

**Comment:**

Glucose values of 100-125 mg/dL indicate impaired fasting glucose.

|                    |      |                |
|--------------------|------|----------------|
| Urea-Nitrogen      | 13   | 7-22 mg/dL     |
| Creatinine, Serum. | 1.1  | 0.6-1.3 mg/dL  |
| Calcium            | 10.8 | 8.4-10.5 mg/dL |
| Total Protein      | 7.5  | 6.0-8.2 g/dL   |
| Albumin            | 5.1  | 3.5-5.3 g/dL   |

| Component   | Value | Range         |
|---|-------|---------------|
| Total Bilirubin.  | 1.5   | 0.1-1.2 mg/dL |
| Alkaline Phosphatase  | 45    | 30-120 U/L    |
| Aspartate Amino Tran  | 24    | 0-37 U/L      |
| Alanine Amino Transf  | 14    | 0-40 U/L      |
| Anion Gap   | 14    | 7-16 mEq/L    |
| SUN/Creatinine Ratio  | 12    |               |
| AST/ALT Ratio   | 1.7   |               |
| Est GFR Afr-Am(MDRD Eqn)  | >60   | mL/min/A      |
| Comment:<br>Estimated GFR is calculated from serum creatinine using the Modification of Diet in Renal Disease (MDRD) equation in patients 18 years or older.<br>Reference Range: >60 mL/min/A, (A=1.73 sq m). |       |               |
| Est GFR NonAfrAm(MDRD Eqn)  | >60   | mL/min/A      |
| Comment:<br>Estimated GFR is calculated from serum creatinine using the Modification of Diet in Renal Disease (MDRD) equation in patients 18 years or older.<br>Reference Range: >60 mL/min/A, (A=1.73 sq m). |       |               |

#### Narrative

Johns Hopkins Medical Labs  
 Zayed B-1065  
 600 North Wolfe Street  
 Baltimore, MD. 21287

#### PSA, TOTAL AND FREE (PSA, TOTAL AND FREE) - Final result (12/27/2012 9:49 AM)

| Component   | Value                 | Range         |           |                       |         |     |          |     |          |     |          |     |       |    |
|---|-----------------------|---------------|-----------|-----------------------|---------|-----|----------|-----|----------|-----|----------|-----|-------|----|
| PSA (Hybritech)   | 3.0                   | 0.0-4.0 ng/mL |           |                       |         |     |          |     |          |     |          |     |       |    |
| Comment:<br>The presence of human anti-mouse antibodies (HAMA), which can result from mouse monoclonal antibodies used for diagnosis or therapy, or heterophile antibodies, may cause an interference in this assay.  |                       |               |           |                       |         |     |          |     |          |     |          |     |       |    |
| PSA, % Free   | 21.7                  | %             |           |                       |         |     |          |     |          |     |          |     |       |    |
| Comment:<br>In Men with total PSA concentrations between 4.0 and 10.0 ng/mL and a non-suspicious digital rectal examination, percent free (unbound) PSA may be used as an aid in distinguishing prostate cancer from benign conditions. In such patients, the probability of cancer is as follows:<br>. <table border="1" style="margin-left: 40px;"> <thead> <tr> <th>%Free PSA</th> <th>Probability of Cancer</th> </tr> </thead> <tbody> <tr> <td>0 - 10%</td> <td>56%</td> </tr> <tr> <td>10 - 15%</td> <td>28%</td> </tr> <tr> <td>15 - 20%</td> <td>20%</td> </tr> <tr> <td>20 - 25%</td> <td>16%</td> </tr> <tr> <td>&gt; 25%</td> <td>8%</td> </tr> </tbody> </table> The clinical utility of percent free PSA for total PSA concentrations outside the 4.0 - 10.0 ng/mL range has not been firmly established. For interpretation or questions, consult the following reference: Partin AW, ..., Chan DW. Analysis of % Free PSA for Prostate Cancer Detection. Urology 1996;48(6A) 55-61. |                       |               | %Free PSA | Probability of Cancer | 0 - 10% | 56% | 10 - 15% | 28% | 15 - 20% | 20% | 20 - 25% | 16% | > 25% | 8% |
| %Free PSA   | Probability of Cancer |               |           |                       |         |     |          |     |          |     |          |     |       |    |
| 0 - 10%   | 56%                   |               |           |                       |         |     |          |     |          |     |          |     |       |    |
| 10 - 15%  | 28%                   |               |           |                       |         |     |          |     |          |     |          |     |       |    |
| 15 - 20%  | 20%                   |               |           |                       |         |     |          |     |          |     |          |     |       |    |
| 20 - 25%  | 16%                   |               |           |                       |         |     |          |     |          |     |          |     |       |    |
| > 25%   | 8%                    |               |           |                       |         |     |          |     |          |     |          |     |       |    |

#### Narrative

Johns Hopkins Medical Labs  
 Meyer B-137  
 600 North Wolfe Street

Narrative

Baltimore, MD. 21287

HEMOGLOBIN A1C - Final result (12/27/2012 9:49 AM)

| Component       | Value | Range     |
|-----------------|-------|-----------|
| Hemoglobin A1C. | 5.7   | 4.5-6.1 % |

Narrative

Johns Hopkins Medical Labs  
Zayed B-1065  
600 North Wolfe Street  
Baltimore, MD. 21287

XR KNEE RT MIN 4 VWS - Final result (04/05/2012 10:27 AM)

Narrative

The Russell H. Morgan Department Of Radiology  
and Radiological Science  
The Johns Hopkins Hospital, Baltimore MD. 21287

ANDREW, CLIFFORD

Exam Date: 04/05/2012 10:27 ORD #90003 Accession #9672186  
History Number: 1636284  
Age: 65Y Sex: M Race: W  
Requester: ANDREW COSGAREA

RESULT:

Bilateral knees, history of right knee pain. Four views right and 3 views left. Bilateral 3 compartment arthritis. Small osteophytes femoral notch on flexion view bilaterally. Bilateral patellofemoral arthritis left greater than right.  
Moderate to marked Prepatellar soft tissue swelling right knee, suggesting bursitis. No evidence of right joint effusion.

IMPRESSION: see above

..:Updated Apr 5 2012 12:19P---

DONNA MAGID MD

DONNA MAGID MD

IMAGES AND INTERPRETATION PERSONALLY READ BY:

DONNA MAGID MD

RESULT ELECTRONICALLY SIGNED

XR KNEE LT 3 VWS - Final result (04/05/2012 10:27 AM)

Narrative

The Russell H. Morgan Department Of Radiology  
and Radiological Science  
The Johns Hopkins Hospital, Baltimore MD. 21287

ANDREW, CLIFFORD

Exam Date: 04/05/2012 10:27 ORD #90003 Accession #9672187  
History Number: 1636284  
Age: 65Y Sex: M Race: W  
Requester: ANDREW COSGAREA

RESULT:

Bilateral knees, history of right knee pain. Four views right and 3 views left. Bilateral 3 compartment arthritis. Small osteophytes femoral notch on flexion view bilaterally. Bilateral patellofemoral arthritis left greater than right.  
Moderate to marked Prepatellar soft tissue swelling right knee, suggesting bursitis. No evidence of right joint effusion.

IMPRESSION: see above

..:Updated Apr 5 2012 12:19P---

DONNA MAGID MD

DONNA MAGID MD

IMAGES AND INTERPRETATION PERSONALLY READ BY:

DONNA MAGID MD



## Narrative

RESULT ELECTRONICALLY SIGNED

## COMPLETE BLOOD COUNT (CBC) WITHOUT DIFFERENTIAL (CBC) - Final result (02/09/2012 8:54 AM)

| Component               | Value | Range             |
|-------------------------|-------|-------------------|
| White Blood Cell Count  | 6040  | 4500-11000 /cu mm |
| Red Blood Cell Count    | 4.72  | 4.50-5.90 M/cu mm |
| Hemoglobin              | 13.9  | 13.9-16.3 g/dL    |
| Hematocrit              | 40.0  | 41.0-53.0 %       |
| Mean Corpuscular Volume | 84.7  | 80.0-100.0 fL     |
| Mean Corpus HgB         | 29.4  | 26.0-34.0 pg      |
| Mean Corpus HgB Conc    | 34.8  | 31.0-37.0 g/dL    |
| RBC Distribution Width  | 12.7  | 11.5-14.5 %       |
| Platelet Count          | 254   | 150-350 K/cu mm   |
| Mean Platelet Volume    | 10.1  | 9.2-12.7 fL       |
| Nucleated RBC Number    | 0     | 0-12 /cu mm       |

## Narrative

Johns Hopkins Medical Labs  
Meyer B-171  
600 North Wolfe Street  
Baltimore, MD. 21287

## COMPREHENSIVE METABOLIC PANEL - Final result (02/09/2012 8:54 AM)

| Component | Value | Range         |
|-----------|-------|---------------|
| Sodium    | 137   | 135-148 mEq/L |
| K-Serum   | 4.8   | 3.5-5.1 mEq/L |
| Chloride  | 99    | 96-109 mEq/L  |
| CO2       | 29    | 21-31 mEq/L   |
| Glucose   | 106   | 60-99 mg/dL   |

Comment: Glucose values of 100-125 mg/dL indicate impaired fasting glucose.

|                          |     |                |
|--------------------------|-----|----------------|
| Urea-Nitrogen            | 19  | 7-22 mg/dL     |
| Creatinine, Serum.       | 0.9 | 0.6-1.3 mg/dL  |
| Calcium                  | 9.7 | 8.4-10.5 mg/dL |
| Total Protein            | 7.2 | 6.0-8.2 g/dL   |
| Albumin                  | 4.5 | 3.5-5.3 g/dL   |
| Total Bilirubin.         | 0.8 | 0.1-1.2 mg/dL  |
| Alkaline Phosphatase     | 42  | 30-120 U/L     |
| Aspartate Amino Tran     | 25  | 0-37 U/L       |
| Alanine Amino Transf     | 19  | 0-40 U/L       |
| Anion Gap                | 9   | 7-16 mEq/L     |
| SUN/Creatinine Ratio     | 21  |                |
| AST/ALT Ratio            | 1.3 |                |
| Est GFR Afr-Am(MDRD Eqn) | >60 | mL/min/A       |

## Comment:

Estimated GFR is calculated from serum creatinine using the Modification of Diet in Renal Disease (MDRD) equation in patients 18 years or older.  
Reference Range: >60 ml/min/A, (A=1.73 sq m).

|                            |     |          |
|----------------------------|-----|----------|
| Est GFR NonAfrAm(MDRD Eqn) | >60 | mL/min/A |
|----------------------------|-----|----------|

## Comment:

Estimated GFR is calculated from serum creatinine using the Modification of Diet in Renal Disease (MDRD) equation in patients 18 years or older.  
Reference Range: >60 ml/min/A, (A=1.73 sq m).

## Narrative

Johns Hopkins Medical Labs  
Meyer B-171  
600 North Wolfe Street  
Baltimore, MD. 21287

## PSA, TOTAL (PSA) - Final result (02/09/2012 8:54 AM)

| Component              | Value | Range         |
|------------------------|-------|---------------|
| Prostate Spec Ag-Tosoh | 2.9   | 0.0-4.0 ng/mL |

## Comment:

The presence of human anti-mouse antibodies (HAMA), which can result from mouse monoclonal antibodies used for diagnosis or therapy, or heterophile antibodies may cause an interference in this assay.

**Narrative**

Johns Hopkins Medical Labs  
 Meyer B-154  
 600 North Wolfe Street  
 Baltimore, MD. 21287

**LIPID PANEL - Final result (02/09/2012 8:54 AM)**

| Component            | Value | Range       |
|----------------------|-------|-------------|
| Cholesterol          | 187   | 0-200 mg/dL |
| Triglycerides        | 85    | 0-150 mg/dL |
| HDL Cholesterol.     | 47    | mg/dL       |
| LDL (Calculated).    | 123   | mg/dL       |
| Total Chol/HDL Ratio | 4.0   | Ratio       |

**Comment:****Reference Range:****Cholesterol**

|                 |               |
|-----------------|---------------|
| Desirable       | < 200 mg/dL   |
| Borderline High | 200-239 mg/dL |
| High            | > 240 mg/dL   |

**Triglyceride**

|                 |               |
|-----------------|---------------|
| Normal          | < 150 mg/dL   |
| Borderline High | 150-199 mg/dL |
| High            | 200-499 mg/dL |
| Very High       | > 500 mg/dL   |

**HDL Cholesterol**

|             |            |
|-------------|------------|
| Undesirable | < 40 mg/dL |
| Desirable   | > 60 mg/dL |

**LDL Cholesterol**

|                 |               |
|-----------------|---------------|
| Optimal         | < 100 mg/dL   |
| Above Optimal   | 100-129 mg/dL |
| Borderline High | 130-159 mg/dL |
| High            | 160-189 mg/dL |
| Very High       | > 190 mg/dL   |

**Categories of risk that modify LDL****Cholesterol Goals**

|                              |             |
|------------------------------|-------------|
| CHD and CHR risk equivalents | < 100 mg/dL |
| Multiple (2+) risk factors   | < 130 mg/dL |
| 0-1 risk factors             | < 160 mg/dL |

**Narrative**

Johns Hopkins Medical Labs  
 Meyer B-171  
 600 North Wolfe Street  
 Baltimore, MD. 21287

**HEMOGLOBIN A1C - Final result (02/09/2012 8:54 AM)**

| Component       | Value | Range     |
|-----------------|-------|-----------|
| Hemoglobin A1C. | 5.6   | 4.5-6.1 % |

**Narrative**

Johns Hopkins Medical Labs  
 Weinberg 2300  
 600 North Wolfe Street  
 Baltimore, MD. 21287

**HIGH SENSITIVITY C-REACTIVE PROTEIN (CRP) (HIGH SENSITIVITY CRP) - Final result (11/18/2010 9:34 AM)**

| Component            | Value | Range |
|----------------------|-------|-------|
| CRP-High Sensitivity | 0.5   | mg/L  |

**Comment:****Relative risk of cardiovascular disease:**

|               |              |
|---------------|--------------|
| Low risk:     | < 1.0 mg/L   |
| Average risk: | 1.0-3.0 mg/L |
| High risk:    | > 3.0 mg/L   |

hsCRP may be affected by acute inflammation;  
 repeat testing of  
 values > 10 mg/L may be necessary if  
 clinically indicated.

Source: Circulation. 2003;107:499-511

**Narrative**

Johns Hopkins Medical Labs  
 Meyer B-171  
 600 North Wolfe Street  
 Baltimore, MD. 21287

**PSA, TOTAL (PSA) - Final result (11/18/2010 9:34 AM)**

| Component              | Value | Range         |
|------------------------|-------|---------------|
| Prostate Spec Ag-Tosoh | 4.0   | 0.0-4.0 ng/mL |

**Comment:**

The presence of human anti-mouse antibodies

| Component | Value   | Range |
|-----------|---|-------|
|           | (HAMA), which can result from mouse monoclonal antibodies used for diagnosis or therapy, or heterophile antibodies may cause an interference in this assay. |       |

**Narrative**

Johns Hopkins Medical Labs  
Meyer B-154  
600 North Wolfe Street  
Baltimore, MD. 21287

**LIPID PANEL - Final result (11/18/2010 9:34 AM)**

| Component            | Value | Range       |
|----------------------|-------|-------------|
| Cholesterol          | 173   | 0-200 mg/dL |
| Triglycerides        | 74    | 0-150 mg/dL |
| HDL Cholesterol.     | 51    | mg/dL       |
| LDL (Calculated).    | 107   | mg/dL       |
| Total Chol/HDL Ratio | 3.4   | Ratio       |

**Comment:**

**Reference Range:**

**Cholesterol**

|                 |               |
|-----------------|---------------|
| Desirable       | < 200 mg/dL   |
| Borderline High | 200-239 mg/dL |
| High            | > 240 mg/dL   |

**Triglyceride**

|                 |               |
|-----------------|---------------|
| Normal          | < 150 mg/dL   |
| Borderline High | 150-199 mg/dL |
| High            | 200-499 mg/dL |
| Very High       | > 500 mg/dL   |

**HDL Cholesterol**

|             |            |
|-------------|------------|
| Undesirable | < 40 mg/dL |
| Desirable   | > 60 mg/dL |

**LDL Cholesterol**

|                 |               |
|-----------------|---------------|
| Optimal         | < 100 mg/dL   |
| Above Optimal   | 100-129 mg/dL |
| Borderline High | 130-159 mg/dL |
| High            | 160-189 mg/dL |
| Very High       | > 190 mg/dL   |

**Categories of risk that modify LDL**

**Cholesterol Goals**

|                              |             |
|------------------------------|-------------|
| CHD and CHR risk equivalents | < 100 mg/dL |
| Multiple (2+) risk factors   | < 130 mg/dL |
| 0-1 risk factors             | < 160 mg/dL |

**Narrative**

Johns Hopkins Medical Labs  
Meyer B-171  
600 North Wolfe Street  
Baltimore, MD. 21287

**COMPREHENSIVE METABOLIC PANEL - Final result (11/18/2010 9:34 AM)**

| Component | Value | Range         |
|-----------|-------|---------------|
| Sodium    | 141   | 135-148 mEq/L |
| K-Serum   | 4.6   | 3.5-5.1 mEq/L |
| Chloride  | 103   | 96-109 mEq/L  |
| CO2.      | 28    | 21-31 mEq/L   |
| Glucose   | 101   | 60-99 mg/dL   |

**Comment:** Glucose values of 100-125 mg/dL indicate impaired fasting glucose.

|                          |      |                |
|--------------------------|------|----------------|
| Urea-Nitrogen            | 16   | 7-22 mg/dL     |
| Creatinine, Serum.       | 0.9  | 0.6-1.3 mg/dL  |
| Calcium                  | 10.0 | 8.4-10.5 mg/dL |
| Total Protein            | 7.4  | 6.0-8.2 g/dL   |
| Albumin                  | 4.6  | 3.5-5.3 g/dL   |
| Total Bilirubin.         | 1.2  | 0.1-1.2 mg/dL  |
| Alkaline Phosphatase     | 43   | 30-120 U/L     |
| Aspartate Amino Tran     | 31   | 0-37 U/L       |
| Alanine Amino Transf     | 18   | 0-40 U/L       |
| Anion Gap                | 10   | 7-16 mEq/L     |
| SUN/Creatinine Ratio     | 18   |                |
| AST/ALT Ratio            | 1.7  |                |
| Est GFR Afr-Am(MDRD Eqn) | >60  | mL/min/A       |

**Comment:**

Estimated GFR is calculated from serum

| Component                  | Value  | Range    |
|----------------------------|--|----------|
|                            | creatinine using the Modification of Diet in Renal Disease (MDRD) equation in patients 18 years or older.<br>Reference Range: >60 ml/min/A, (A=1.73 sq m).   |          |
| Est GFR NonAfrAm(MDRD Eqn) | >60  | mL/min/A |
|                            | <b>Comment:</b><br>Estimated GFR is calculated from serum creatinine using the Modification of Diet in Renal Disease (MDRD) equation in patients 18 years or older.<br>Reference Range: >60 ml/min/A, (A=1.73 sq m). |          |

#### Narrative

Johns Hopkins Medical Labs  
Meyer B-171  
600 North Wolfe Street  
Baltimore, MD. 21287

#### COMPLETE BLOOD COUNT (CBC) WITHOUT DIFFERENTIAL (CBC) - Final result (11/18/2010 9:34 AM)

| Component               | Value | Range             |
|-------------------------|-------|-------------------|
| White Blood Cell Count  | 6220  | 4500-11000 /cu mm |
| Red Blood Cell Count    | 4.68  | 4.50-5.90 M/cu mm |
| Hemoglobin              | 13.6  | 13.9-16.3 g/dL    |
| Hematocrit              | 40.1  | 41.0-53.0 %       |
| Mean Corpuscular Volume | 85.7  | 80.0-100.0 fL     |
| Mean Corpus HgB         | 29.1  | 26.0-34.0 pg      |
| Mean Corpus HgB Conc    | 33.9  | 31.0-37.0 g/dL    |
| RBC Distribution Width  | 12.8  | 11.5-14.5 %       |
| Platelet Count          | 228   | 150-350 K/cu mm   |
| Mean Platelet Volume    | 10.5  | 9.2-12.7 fL       |
| Nucleated RBC Number    | 0     | 0-12 /cu mm       |

#### Narrative

Johns Hopkins Medical Labs  
Meyer B-171  
600 North Wolfe Street  
Baltimore, MD. 21287

#### COMPREHENSIVE METABOLIC PANEL - Final result (05/13/2010 9:02 AM)

| Component                  | Value  | Range          |
|----------------------------|--|----------------|
| Sodium                     | 142  | 135-148 mEq/L  |
| K-Serum                    | 4.4  | 3.5-5.1 mEq/L  |
| Chloride                   | 103  | 96-109 mEq/L   |
| CO2                        | 28   | 21-31 mEq/L    |
| Glucose                    | 107  | 60-99 mg/dL    |
|                            | <b>Comment:</b> Glucose values of 100-125 mg/dL indicate impaired fasting glucose.   |                |
| Urea-Nitrogen              | 11   | 7-22 mg/dL     |
| Creatinine, Serum.         | 1.0  | 0.6-1.3 mg/dL  |
| Calcium                    | 9.9  | 8.4-10.5 mg/dL |
| Total Protein              | 7.2  | 6.0-8.2 g/dL   |
| Albumin                    | 4.4  | 3.5-5.3 g/dL   |
| Total Bilirubin.           | 1.2  | 0.1-1.2 mg/dL  |
| Alkaline Phosphatase       | 41   | 30-120 U/L     |
| Aspartate Amino Tran       | 23   | 0-37 U/L       |
| Alanine Amino Transf       | 16   | 0-40 U/L       |
| Anion Gap                  | 15   | 11-20 mEq/L    |
| SUN/Creatinine Ratio       | 11   |                |
| AST/ALT Ratio              | 1.4  |                |
| Est GFR Afr-Am(MDRD Eqn)   | >60  | mL/min/A       |
|                            | <b>Comment:</b><br>Estimated GFR is calculated from serum creatinine using the Modification of Diet in Renal Disease (MDRD) equation in patients 18 years or older.<br>Reference Range: >60 ml/min/A, (A=1.73 sq m). |                |
| Est GFR NonAfrAm(MDRD Eqn) | >60  | mL/min/A       |
|                            | <b>Comment:</b><br>Estimated GFR is calculated from serum creatinine using the Modification of Diet in Renal Disease (MDRD) equation in patients 18 years or older.<br>Reference Range: >60 ml/min/A, (A=1.73 sq m). |                |

**Narrative**

Johns Hopkins Medical Labs  
 Meyer B-171  
 600 North Wolfe Street  
 Baltimore, MD. 21287

**LIPID PANEL - Final result (05/13/2010 9:02 AM)**

| Component            | Value | Range       |
|----------------------|-------|-------------|
| Cholesterol          | 157   | 0-200 mg/dL |
| Triglycerides        | 126   | 0-150 mg/dL |
| HDL Cholesterol.     | 50    | mg/dL       |
| LDL (Calculated).    | 82    | mg/dL       |
| Total Chol/HDL Ratio | 3.1   | Ratio       |

**Comment:****Reference Range:****Cholesterol**

Desirable < 200 mg/dL  
 Borderline High 200-239 mg/dL  
 High > 240 mg/dL

**Triglyceride**

Normal < 150 mg/dL  
 Borderline High 150-199 mg/dL  
 High 200-499 mg/dL  
 Very High > 500 mg/dL

**HDL Cholesterol**

Undesirable < 40 mg/dL  
 Desirable > 60 mg/dL

**LDL Cholesterol**

Optimal < 100 mg/dL  
 Above Optimal 100-129 mg/dL  
 Borderline High 130-159 mg/dL  
 High 160-189 mg/dL  
 Very High > 190 mg/dL

**Categories of risk that modify LDL****Cholesterol Goals**

CHD and CHR risk equivalents < 100 mg/dL  
 Multiple (2+) risk factors < 130 mg/dL  
 0-1 risk factors < 160 mg/dL

**Narrative**

Johns Hopkins Medical Labs  
 Meyer B-171  
 600 North Wolfe Street  
 Baltimore, MD. 21287

**HEMOGLOBIN A1C - Final result (05/13/2010 9:02 AM)**

| Component       | Value | Range     |
|-----------------|-------|-----------|
| Hemoglobin A1C. | 5.8   | 4.5-6.1 % |

**Narrative**

Johns Hopkins Medical Labs  
 Weinberg 2300  
 600 North Wolfe Street  
 Baltimore, MD. 21287

**MRI IAC W/WO Contrast (MRI IAC W/WO CONTRAST) - Final result (04/22/2010 8:34 AM)****Narrative**

The Russell H. Morgan Department Of Radiology  
 and Radiological Science  
 The Johns Hopkins Hospital, Baltimore MD. 21287

ANDREW, CLIFFORD

Exam Date: 04/22/2010 08:34 ORD #90001 Accession #7020543  
 History Number: 1636284  
 Age: 63Y Sex: M Race: W  
 Requester: DANIEL ERNEST FORD

RESULT: INDICATION: History of hypertension.

TECHNIQUE: Sagittal T1, axial FLAIR, diffusion weighted imaging with ADC map, axial T1, axial T2, axial and coronal postcontrast images.

COMPARISON: 4/1/96 report, images are not available for direct comparison.

**FINDINGS:**

There is moderate left occipital plagiocephaly. The corpus callosum is intact. The craniocervical junction is unremarkable. The visualized sella

**Narrative**

and sellar contents are unremarkable. There are minimal scattered periventricular and subcortical white matter FLAIR hyperintensities, which are nonspecific, possibly reflecting small vessel ischemic change in a patient of this age. There is no evidence of mass or mass effect. On the postcontrast images there is no abnormal enhancement. No evidence of hydrocephalus. No restricted diffusion is seen.

The included orbits and globes are unremarkable. There is trivial mucoperiosteal thickening within the ethmoid sinuses. The mastoid air cells are clear. The visualized major intracranial flow voids are intact. No abnormal enhancement is seen within the brain parenchyma or meninges.

**IMPRESSION:**

Essentially unremarkable MR examination of the brain except for minimal, likely small vessel ischemic disease and moderate left occipital plagiocephaly.

..: Transcribed By GKU. Last update: Apr 22 2010 11:17A.

GEORGE P KUO MD

**IMAGES AND INTERPRETATION PERSONALLY REVIEWED BY:**

DORIS DA MAY LIN MD PHD

**LIPID PANEL - Final result (11/19/2009 7:14 AM)**

| Component            | Value | Range       |
|----------------------|-------|-------------|
| Cholesterol          | 212   | 0-200 mg/dL |
| Triglycerides        | 90    | 0-150 mg/dL |
| HDL Cholesterol.     | 52    | mg/dL       |
| LDL (Calculated).    | 142   | mg/dL       |
| Total Chol/HDL Ratio | 4.1   | Ratio       |

**Comment:**

**Reference Range:**

**Cholesterol**

|                 |               |
|-----------------|---------------|
| Desirable       | < 200 mg/dL   |
| Borderline High | 200-239 mg/dL |
| High            | > 240 mg/dL   |

**Triglyceride**

|                 |               |
|-----------------|---------------|
| Normal          | < 150 mg/dL   |
| Borderline High | 150-199 mg/dL |
| High            | 200-499 mg/dL |
| Very High       | > 500 mg/dL   |

**HDL Cholesterol**

|             |            |
|-------------|------------|
| Undesirable | < 40 mg/dL |
| Desirable   | > 60 mg/dL |

**LDL Cholesterol**

|                 |               |
|-----------------|---------------|
| Optimal         | < 100 mg/dL   |
| Above Optimal   | 100-129 mg/dL |
| Borderline High | 130-159 mg/dL |
| High            | 160-189 mg/dL |
| Very High       | > 190 mg/dL   |

**Categories of risk that modify LDL**

**Cholesterol Goals**

|                              |             |
|------------------------------|-------------|
| CHD and CHR risk equivalents | < 100 mg/dL |
| Multiple (2+) risk factors   | < 130 mg/dL |
| 0-1 risk factors             | < 160 mg/dL |

**Narrative**

Johns Hopkins Medical Labs  
Meyer B-171  
600 North Wolfe Street  
Baltimore, MD. 21287

**HEMOGLOBIN A1C - Final result (11/19/2009 7:14 AM)**

| Component       | Value | Range     |
|-----------------|-------|-----------|
| Hemoglobin A1C. | 5.8   | 4.5-6.1 % |

**Narrative**

Johns Hopkins Medical Labs  
Weinberg 2300  
600 North Wolfe Street  
Baltimore, MD. 21287

**COMPREHENSIVE METABOLIC PANEL - Final result (11/19/2009 7:14 AM)**

| Component | Value | Range         |
|-----------|-------|---------------|
| Sodium    | 135   | 135-148 mEq/L |

| Component   | Value | Range          |
|---|-------|----------------|
| K-Serum   | 4.1   | 3.5-5.1 mEq/L  |
| Chloride  | 98    | 96-109 mEq/L   |
| CO2.  | 26    | 21-31 mEq/L    |
| Glucose   | 105   | 60-99 mg/dL    |
| Comment: Glucose values of 100-125 mg/dL indicate impaired fasting glucose.   |       |                |
| Urea-Nitrogen   | 15    | 7-22 mg/dL     |
| Creatinine, Serum.  | 1.0   | 0.6-1.3 mg/dL  |
| Calcium   | 9.9   | 8.4-10.5 mg/dL |
| Total Protein   | 7.6   | 6.0-8.2 g/dL   |
| Albumin   | 4.7   | 3.5-5.3 g/dL   |
| Total Bilirubin.  | 1.4   | 0.1-1.2 mg/dL  |
| Alkaline Phosphatase  | 39    | 30-120 U/L     |
| Aspartate Amino Tran  | 27    | 0-37 U/L       |
| Alanine Amino Transf  | 18    | 0-40 U/L       |
| Anion Gap   | 15    | 11-20 mEq/L    |
| SUN/Creatinine Ratio  | 15    |                |
| AST/ALT Ratio   | 1.5   |                |
| Est GFR Afr-Am(MDRD Eqn)  | >60   | mL/min/A       |
| Comment:<br>Estimated GFR is calculated from serum creatinine using the Modification of Diet in Renal Disease (MDRD) equation in patients 18 years or older.<br>Reference Range: >60 ml/min/A, (A=1.73 sq m). |       |                |
| Est GFR NonAfrAm(MDRD Eqn)  | >60   | mL/min/A       |
| Comment:<br>Estimated GFR is calculated from serum creatinine using the Modification of Diet in Renal Disease (MDRD) equation in patients 18 years or older.<br>Reference Range: >60 ml/min/A, (A=1.73 sq m). |       |                |

#### Narrative

Johns Hopkins Medical Labs  
Meyer B-171  
600 North Wolfe Street  
Baltimore, MD. 21287

#### PSA, TOTAL (PSA) - Final result (11/19/2009 7:14 AM)

| Component   | Value | Range         |
|---|-------|---------------|
| Prostate Spec Ag-Tosoh  | 2.2   | 0.0-4.0 ng/mL |
| Comment:<br>The presence of human anti-mouse antibodies (HAMA), which can result from mouse monoclonal antibodies used for diagnosis or therapy, or heterophile antibodies may cause an interference in this assay. |       |               |

#### Narrative

Johns Hopkins Medical Labs  
Meyer B-154  
600 North Wolfe Street  
Baltimore, MD. 21287

#### COMPREHENSIVE METABOLIC PANEL - Final result (07/09/2009 7:16 AM)

| Component   | Value | Range          |
|---|-------|----------------|
| Sodium  | 141   | 135-148 mEq/L  |
| K-Serum   | 4.2   | 3.5-5.1 mEq/L  |
| Chloride  | 102   | 96-109 mEq/L   |
| CO2.  | 27    | 21-31 mEq/L    |
| Glucose   | 110   | 60-99 mg/dL    |
| Comment: Glucose values of 100-125 mg/dL indicate impaired fasting glucose. |       |                |
| Urea-Nitrogen   | 15    | 7-22 mg/dL     |
| Creatinine, Serum.  | 1.0   | 0.6-1.3 mg/dL  |
| Calcium   | 10.2  | 8.4-10.5 mg/dL |
| Total Protein   | 7.4   | 6.0-8.2 g/dL   |
| Albumin   | 4.6   | 3.5-5.3 g/dL   |
| Total Bilirubin.  | 1.0   | 0.1-1.2 mg/dL  |
| Alkaline Phosphatase  | 44    | 30-120 U/L     |
| Aspartate Amino Tran  | 23    | 0-37 U/L       |
| Alanine Amino Transf  | 19    | 0-40 U/L       |
| Anion Gap   | 16    | 11-20 mEq/L    |

| Component   | Value | Range    |
|---|-------|----------|
| SUN/Creatinine Ratio  | 15    |          |
| AST/ALT Ratio   | 1.2   |          |
| Est GFR Afr-Am(MDRD Eqn)  | >60   | mL/min/A |
| Comment:<br>Estimated GFR is calculated from serum creatinine using the Modification of Diet in Renal Disease (MDRD) equation in patients 18 years or older.<br>Reference Range: >60 ml/min/A, (A=1.73 sq m). |       |          |
| Est GFR NonAfrAm(MDRD Eqn)  | >60   | mL/min/A |
| Comment:<br>Estimated GFR is calculated from serum creatinine using the Modification of Diet in Renal Disease (MDRD) equation in patients 18 years or older.<br>Reference Range: >60 ml/min/A, (A=1.73 sq m). |       |          |

**Narrative**

Johns Hopkins Medical Labs  
 Meyer B-171  
 600 North Wolfe Street  
 Baltimore, MD. 21287

**LIPID PANEL - Final result (07/09/2009 7:16 AM)**

| Component  | Value | Range       |
|--|-------|-------------|
| Cholesterol  | 197   | 0-200 mg/dL |
| Triglycerides  | 124   | 0-150 mg/dL |
| HDL Cholesterol.   | 53    | mg/dL       |
| LDL (Calculated).  | 119   | mg/dL       |
| Total Chol/HDL Ratio   | 3.7   | Ratio       |
| Comment:<br>Reference Range:<br>Cholesterol<br>Desirable < 200 mg/dL<br>Borderline High 200-239 mg/dL<br>High > 240 mg/dL<br>Triglyceride<br>Normal < 150 mg/dL<br>Borderline High 150-199 mg/dL<br>High 200-499 mg/dL<br>Very High > 500 mg/dL<br>HDL Cholesterol<br>Undesirable < 40 mg/dL<br>Desirable > 60 mg/dL<br>LDL Cholesterol<br>Optimal < 100 mg/dL<br>Above Optimal 100-129 mg/dL<br>Borderline High 130-159 mg/dL<br>High 160-189 mg/dL<br>Very High > 190 mg/dL<br>Categories of risk that modify LDL<br>Cholesterol Goals<br>CHD and CHR risk equivalents < 100 mg/dL<br>Multiple (2+) risk factors < 130 mg/dL<br>0-1 risk factors < 160 mg/dL |       |             |

**Narrative**

Johns Hopkins Medical Labs  
 Meyer B-171  
 600 North Wolfe Street  
 Baltimore, MD. 21287

**XR PELVIS AND HIP RT 2 VWS - Final result (06/20/2009 6:28 PM)**

**Narrative**

The Russell H. Morgan Department Of Radiology  
 and Radiological Science  
 The Johns Hopkins Hospital, Baltimore MD. 21287

ANDREW, CLIFFORD

Exam Date: 06/20/2009 18:28 ORD #90002 Accession #6470562  
 History Number: 1636284  
 Age: 62Y Sex: M Race: W  
 Requester: JOY ELIZABETH CROOK MD



Narrative

ACC:6470562

RESULT:

AP pelvis and right hip

INDICATION: Pain. Fall.

COMPARISON: None available in PACS

IMPRESSION:

Normal with probable injection granuloma left hip.

..:Updated Jul 13 2009 5:51P---

EZANA MULUNEH AZENE MD PHD

ROHAN PIYASENA MD

IMAGES AND INTERPRETATION PERSONALLY REVIEWED BY:

ROHAN PIYASENA MD

XR ELBOW LT 2 VWS - Final result (06/20/2009 5:18 PM)

Narrative

The Russell H. Morgan Department Of Radiology  
and Radiological Science  
The Johns Hopkins Hospital, Baltimore MD. 21287

ANDREW, CLIFFORD

Exam Date: 06/20/2009 17:18 ORD #90001 Accession #6470555  
History Number: 1636284  
Age: 62Y Sex: M Race: W  
Requester: JOY ELIZABETH CROOK MD

EXAM: DGE 5260 - ELBOW LEFT 2 VIEWS - Jun 20, 2009 17:18 ACC:6470555

RESULT:

Left elbow two views

INDICATION: Pain. Fell off bike.

COMPARISON: None available in PACS

IMPRESSION:

Soft tissue swelling anterior and lateral to medial epicondyle and  
posterior to elbow joint.  
No joint effusion or acute fracture.

..:Updated Jul 13 2009 5:42P---

EZANA MULUNEH AZENE MD PHD

ROHAN PIYASENA MD

IMAGES AND INTERPRETATION PERSONALLY REVIEWED BY:

ROHAN PIYASENA MD

LIPID PANEL - Final result (03/19/2009 8:45 AM)

| Component            | Value | Range       |
|----------------------|-------|-------------|
| Cholesterol          | 232   | 0-200 mg/dL |
| Triglycerides        | 161   | 0-150 mg/dL |
| HDL Cholesterol.     | 47    | mg/dL       |
| LDL (Calculated).    | 153   | mg/dL       |
| Total Chol/HDL Ratio | 4.9   | Ratio       |

Comment:

Reference Range:

|                 |               |
|-----------------|---------------|
| Cholesterol     |               |
| Desirable       | < 200 mg/dL   |
| Borderline High | 200-239 mg/dL |
| High            | > 240 mg/dL   |
| Triglyceride    |               |
| Normal          | < 150 mg/dL   |
| Borderline High | 150-199 mg/dL |
| High            | 200-499 mg/dL |
| Very High       | > 500 mg/dL   |
| HDL Cholesterol |               |
| Undesirable     | < 40 mg/dL    |
| Desirable       | > 60 mg/dL    |

| Component                          | Value         | Range |
|------------------------------------|---------------|-------|
| LDL Cholesterol                    |               |       |
| Optimal                            | < 100 mg/dL   |       |
| Above Optimal                      | 100-129 mg/dL |       |
| Borderline High                    | 130-159 mg/dL |       |
| High                               | 160-189 mg/dL |       |
| Very High                          | > 190 mg/dL   |       |
| Categories of risk that modify LDL |               |       |
| Cholesterol Goals                  |               |       |
| CHD and CHR risk equivalents       | < 100 mg/dL   |       |
| Multiple (2+) risk factors         | < 130 mg/dL   |       |
| 0-1 risk factors                   | < 160 mg/dL   |       |

**Narrative**

Johns Hopkins Medical Labs  
Meyer B-171  
600 North Wolfe Street  
Baltimore, MD. 21287

**COMPLETE BLOOD COUNT (CBC) WITHOUT DIFFERENTIAL (CBC) - Final result (09/04/2008 7:55 AM)**

| Component               | Value | Range             |
|-------------------------|-------|-------------------|
| White Blood Cell Count  | 6560  | 4500-11000 /cu mm |
| Red Blood Cell Count    | 4.60  | 4.50-5.90 M/cu mm |
| Hemoglobin              | 13.5  | 13.9-16.3 g/dL    |
| Hematocrit              | 39.0  | 41.0-53.0 %       |
| Mean Corpuscular Volume | 84.8  | 80.0-100.0 fL     |
| Mean Corpus Hgb         | 29.3  | 26.0-34.0 pg      |
| Mean Corpus Hgb Conc    | 34.6  | 31.0-37.0 g/dL    |
| RBC Distribution Width  | 12.8  | 11.5-14.5 %       |
| Platelet Count          | 308   | 150-350 K/cu mm   |
| Mean Platelet Volume    | 9.7   | 9.2-12.7 fL       |
| Nucleated RBC Number    | 0     | 0-12 /cu mm       |

**Narrative**

Johns Hopkins Medical Labs  
Meyer B-171  
600 North Wolfe Street  
Baltimore, MD. 21287

**LIPID PANEL - Final result (09/04/2008 7:55 AM)**

| Component            | Value | Range       |
|----------------------|-------|-------------|
| Cholesterol          | 222   | 0-200 mg/dL |
| Triglycerides        | 115   | 0-150 mg/dL |
| HDL Cholesterol      | 52    | mg/dL       |
| LDL (Calculated)     | 147   | mg/dL       |
| Total Chol/HDL Ratio | 4.3   | Ratio       |

**Comment:**

**Reference Range:**

**Cholesterol**

|                 |               |
|-----------------|---------------|
| Desirable       | < 200 mg/dL   |
| Borderline High | 200-239 mg/dL |
| High            | > 240 mg/dL   |

**Triglyceride**

|                 |               |
|-----------------|---------------|
| Normal          | < 150 mg/dL   |
| Borderline High | 150-199 mg/dL |
| High            | 200-499 mg/dL |
| Very High       | > 500 mg/dL   |

**HDL Cholesterol**

|             |            |
|-------------|------------|
| Undesirable | < 40 mg/dL |
| Desirable   | > 60 mg/dL |

**LDL Cholesterol**

|                 |               |
|-----------------|---------------|
| Optimal         | < 100 mg/dL   |
| Above Optimal   | 100-129 mg/dL |
| Borderline High | 130-159 mg/dL |
| High            | 160-189 mg/dL |
| Very High       | > 190 mg/dL   |

**Categories of risk that modify LDL**

**Cholesterol Goals**

|                              |             |
|------------------------------|-------------|
| CHD and CHR risk equivalents | < 100 mg/dL |
| Multiple (2+) risk factors   | < 130 mg/dL |
| 0-1 risk factors             | < 160 mg/dL |

**Narrative**

Johns Hopkins Medical Labs  
Meyer B-171  
600 North Wolfe Street  
Baltimore, MD. 21287

**COMPREHENSIVE METABOLIC PANEL - Final result (09/04/2008 7:55 AM)**

| Component | Value | Range         |
|-----------|-------|---------------|
| Sodium    | 141   | 135-148 mEq/L |

| Component   | Value | Range          |
|---|-------|----------------|
| K-Serum   | 4.4   | 3.5-5.1 mEq/L  |
| Chloride  | 103   | 96-109 mEq/L   |
| Urea-Nitrogen   | 15    | 7-22 mg/dL     |
| Glucose   | 104   | 60-99 mg/dL    |
| Comment: Glucose values of 100-125 mg/dL indicate impaired fasting glucose.   |       |                |
| Creatinine, Serum.  | 0.9   | 0.6-1.3 mg/dL  |
| Calcium   | 10.3  | 8.4-10.5 mg/dL |
| Total Protein   | 7.2   | 6.0-8.2 g/dL   |
| Albumin   | 4.2   | 3.5-5.3 g/dL   |
| Total Bilirubin.  | 0.9   | 0.1-1.2 mg/dL  |
| Alanine Amino Transf  | 18    | 0-40 U/L       |
| Aspartate Amino Tran  | 21    | 0-37 U/L       |
| Alkaline Phosphatase  | 45    | 30-120 U/L     |
| CO2.  | 27    | 21-31 mEq/L    |
| Anion Gap   | 15    | 11-20 mEq/L    |
| SUN/Creatinine Ratio  | 17    |                |
| AST/ALT Ratio   | 1.2   |                |
| Est GFR Afr-Am(MDRD Eqn)  | >60   | mL/min/A       |
| Comment:<br>Estimated GFR is calculated from serum creatinine using the Modification of Diet in Renal Disease (MDRD) equation in patients 18 years or older.<br>Reference Range: >60 ml/min/A, (A=1.73 sq m). |       |                |
| Est GFR NonAfrAm(MDRD Eqn)  | >60   | mL/min/A       |
| Comment:<br>Estimated GFR is calculated from serum creatinine using the Modification of Diet in Renal Disease (MDRD) equation in patients 18 years or older.<br>Reference Range: >60 ml/min/A, (A=1.73 sq m). |       |                |

#### Narrative

Johns Hopkins Medical Labs  
Meyer B-171  
600 North Wolfe Street  
Baltimore, MD. 21287

#### PSA, TOTAL (PSA) - Final result (09/04/2008 7:55 AM)

| Component   | Value | Range         |
|---|-------|---------------|
| Prostate Spec Ag-Tosoh  | 2.3   | 0.0-4.0 ng/mL |
| Comment:<br>The presence of human anti-mouse antibodies (HAMA), which can result from mouse monoclonal antibodies used for diagnosis or therapy, or heterophile antibodies may cause an interference in this assay. |       |               |

#### Narrative

Johns Hopkins Medical Labs  
Meyer B-154  
600 North Wolfe Street  
Baltimore, MD. 21287

#### LIPID PANEL - Final result (11/08/2007 5:00 PM)

| Component  | Value | Range       |
|--|-------|-------------|
| Cholesterol  | 256   | 0-200 mg/dL |
| Triglycerides  | 102   | 0-150 mg/dL |
| HDL Cholesterol.   | 48    | mg/dL       |
| LDL (Calculated).  | 188   | mg/dL       |
| Total Chol/HDL Ratio   | 5.3   | Ratio       |
| Comment:<br>Reference Range:<br>Cholesterol<br>Desirable < 200 mg/dL<br>Borderline High 200-239 mg/dL<br>High > 240 mg/dL<br>Triglyceride<br>Normal < 150 mg/dL<br>Borderline High 150-199 mg/dL<br>High 200-499 mg/dL<br>Very High > 500 mg/dL<br>HDL Cholesterol<br>Undesirable < 40 mg/dL |       |             |

| Component | Value                              | Range         |
|-----------|------------------------------------|---------------|
|           | Desirable                          | > 60 mg/dL    |
|           | LDL Cholesterol                    |               |
|           | Optimal                            | < 100 mg/dL   |
|           | Above Optimal                      | 100-129 mg/dL |
|           | Borderline High                    | 130-159 mg/dL |
|           | High                               | 160-189 mg/dL |
|           | Very High                          | > 190 mg/dL   |
|           | Categories of risk that modify LDL |               |
|           | Cholesterol Goals                  |               |
|           | CHD and CHR risk equivalents       | < 100 mg/dL   |
|           | Multiple (2+) risk factors         | < 130 mg/dL   |
|           | 0-1 risk factors                   | < 160 mg/dL   |

#### Narrative

Johns Hopkins Medical Labs  
Meyer B-171  
600 North Wolfe Street  
Baltimore, MD. 21287

#### XR WRIST LT 2 VWS - Final result (11/08/2007)

##### Narrative

The Russell H. Morgan Department Of Radiology  
and Radiological Science  
The Johns Hopkins Hospital, Baltimore MD. 21287

ANDREW, CLIFFORD

Exam Date: 11/08/2007 16:21 ORD #90003 Accession #5464884  
History Number: 1636284  
Age: 61Y Sex: M Race: W  
Requester: DANIEL E FORD M.D.

EXAM: DOJ 5860 - WRIST, LEFT - Nov 08, 2007 16:21 ACC:5464884

##### RESULT:

History of wrist pain and impending surgery. The lungs are clear on this one view

##### IMPRESSION:

..:Updated Nov 8 2007 5:05P---

DONNA MAGID M.D.

##### IMAGES AND INTERPRETATION PERSONALLY READ BY:

DONNA MAGID M.D.

#### XR WRIST LT 2 VWS - Final result (08/30/2007)

##### Narrative

The Russell H. Morgan Department Of Radiology  
and Radiological Science  
The Johns Hopkins Hospital, Baltimore MD. 21287

ANDREW, CLIFFORD

Exam Date: 08/30/2007 12:29 ORD #90002 Accession #5351228  
History Number: 1636284  
Age: 60Y Sex: M Race: W  
Requester: FRANK J. FRASSICA M.D.

EXAM: DOJ 5860 - WRIST, LEFT - Aug 30, 2007 12:29 ACC:5351228

##### RESULT:

TECHNIQUE: Left wrist, three views.

GIVEN HISTORY AND INDICATION: WRIST FX .

COMPARISON: None available.

##### IMPRESSION:

Status post intra-articular distal radius fracture with internal fixation with T-plate and screws. Near anatomic alignment.

..:Updated Aug 30 2007 3:41P---

JAN FRITZ MD

Narrative

DONNA MAGID M.D.

IMAGES AND INTERPRETATION PERSONALLY REVIEWED BY:

DONNA MAGID M.D.

**ECG 12-LEAD (EKG 12-LEAD) - Final result (08/09/2007 5:45 PM)**

Narrative

THE \* HISTORY NO.: 001636284  
 JOHNS HOPKINS \* NAME: ANDREW, CLIFFORD  
 HOSPITAL \* AGE/ RACE/ SEX: 60 Years WHITE MALE  
 \* LOCATION: JHOC-S  
 \* REFERRED BY:  
 ELECTROCARDIOGRAM \* ATTENDING M.D.:  
 REPORT \* DATE / TIME: 08/09/07 @ 17:45

INDICATION FOR STUDY: preop

|                  |     |         |
|------------------|-----|---------|
| Ventricular Rate | 68  | BPM     |
| Atrial Rate      | 68  | BPM     |
| P-R Interval     | 160 | ms      |
| QRS Duration     | 98  | ms      |
| QT Interval      | 408 | ms      |
| QTc Interval     | 433 | ms      |
| P Axis           | 68  | degrees |
| R Axis           | 7   | degrees |
| T Axis           | 42  | degrees |

NORMAL SINUS RHYTHM  
 RSR' IN LEAD V1  
 BORDERLINE ECG  
 NO SIGNIFICANT CHANGE SINCE 11/13/06

GC: N

Confirmed by: WENDY POST, M.D.

Technician: oa

Note: This note provides information pertaining only to a specific event. A more detailed medical history is available in the Medical Record.

**COMPLETE BLOOD COUNT (CBC) WITHOUT DIFFERENTIAL (CBC) - Final result (08/09/2007 5:35 PM)**

| Component               | Value | Range             |
|-------------------------|-------|-------------------|
| White Blood Cell Count  | 7940  | 4500-11000 /cu mm |
| Red Blood Cell Count    | 4.17  | 4.50-5.90 M/cu mm |
| Hemoglobin              | 12.0  | 13.9-16.3 g/dL    |
| Hematocrit              | 34.4  | 41.0-53.0 %       |
| Mean Corpuscular Volume | 82.5  | 80.0-100.0 fL     |
| Mean Corpus Hgb         | 28.8  | 26.0-34.0 pg      |
| Mean Corpus Hgb Conc    | 34.9  | 31.0-37.0 g/dL    |
| RBC Distribution Width  | 13.1  | 11.5-14.5 %       |
| Platelet Count          | 363   | 150-350 K/cu mm   |
| Mean Platelet Volume    | 8.6   | 9.2-12.7 fL       |
| Nucleated RBC Number    | 0     | 0-12 /cu mm       |

Narrative

Johns Hopkins Medical Labs  
 Meyer B-171  
 600 North Wolfe Street  
 Baltimore, MD. 21287

**BASIC METABOLIC PANEL - Final result (08/09/2007 5:35 PM)**

| Component   | Value | Range          |
|---|-------|----------------|
| Sodium  | 141   | 135-148 mEq/L  |
| K-Serum   | 4.0   | 3.5-5.1 mEq/L  |
| Chloride  | 103   | 96-109 mEq/L   |
| CO2   | 29    | 21-31 mEq/L    |
| Urea-Nitrogen   | 18    | 7-22 mg/dL     |
| Creatinine, Serum.  | 0.9   | 0.6-1.3 mg/dL  |
| Glucose   | 94    | 60-99 mg/dL    |
| Comment: Glucose values of 100-125 mg/dL indicate impaired fasting glucose. |       |                |
| Calcium   | 10.2  | 8.4-10.5 mg/dL |
| Anion Gap   | 13    | 11-20 mEq/L    |
| SUN/Creatinine Ratio  | 20    |                |
| Est GFR Afr-Am(MDRD Eqn)  | >60   | mL/min/A       |

Comment:  
 Estimated GFR is calculated from serum creatinine using the Modification of Diet in Renal Disease (MDRD)

| Component   | Value | Range    |
|---|-------|----------|
| Est GFR NonAfrAm(MDRD Eqn)  | >60   | mL/min/A |
| equation in patients<br>18 years or older (Am J Kidney Dis.<br>2002,39:524). Reference ranges:<br>>60 ml/min/A, (A=1.73 sq m).  |       |          |
| <b>Comment:</b><br>Estimated GFR is calculated from serum<br>creatinine using the<br>Modification of Diet in Renal Disease (MDRD)<br>equation in patients<br>18 years or older (Am J Kidney Dis.<br>2002,39:524). Reference ranges:<br>>60 ml/min/A, (A=1.73 sq m). |       |          |

#### Narrative

Johns Hopkins Medical Labs  
 Meyer B-171  
 600 North Wolfe Street  
 Baltimore, MD. 21287

#### PSA, TOTAL (PSA) - Final result (06/15/2007 5:32 PM)

| Component   | Value | Range         |
|---|-------|---------------|
| Prostate Spec Ag-Tosoh  | 2.3   | 0.0-4.0 ng/mL |
| <b>Comment:</b><br>The presence of human anti-mouse antibodies<br>(HAMA), which can result<br>from mouse monoclonal antibodies used for<br>diagnosis or therapy,<br>or heterophile antibodies may cause an<br>interference in this assay. |       |               |

#### Narrative

Johns Hopkins Medical Labs  
 Meyer B-154  
 600 North Wolfe Street  
 Baltimore, MD. 21287

#### LIPID PANEL - Final result (06/15/2007 5:32 PM)

| Component   | Value | Range       |
|---|-------|-------------|
| Cholesterol   | 256   | 0-200 mg/dL |
| Triglycerides   | 74    | 0-150 mg/dL |
| HDL Cholesterol.  | 49    | mg/dL       |
| LDL (Calculated).   | 192   | mg/dL       |
| Total Chol/HDL Ratio  | 5.2   | Ratio       |
| <b>Comment:</b><br>Reference Range:<br>Cholesterol<br>Desirable < 200 mg/dL<br>Borderline High 200-239 mg/dL<br>High > 240 mg/dL<br>Triglyceride<br>Normal < 150 mg/dL<br>Borderline High 150-199 mg/dL<br>High 200-499 mg/dL<br>Very High > 500 mg/dL<br>HDL Cholesterol<br>Undesirable < 40 mg/dL<br>Desirable > 60 mg/dL<br>LDL Cholesterol<br>Optimal < 100 mg/dL<br>Above Optimal 100-129 mg/dL<br>Borderline High 130-159 mg/dL<br>High 160-189 mg/dL<br>Very High > 190 mg/dL<br>Categories of risk that modify LDL<br>Cholesterol Goals<br>CHD and CHR risk equivalents < 100 mg/dL<br>Multiple (2+) risk factors < 130 mg/dL<br>0-1 risk factors < 160 mg/dL |       |             |

#### Narrative

Johns Hopkins Medical Labs  
 Meyer B-171  
 600 North Wolfe Street  
 Baltimore, MD. 21287

#### COMPREHENSIVE METABOLIC PANEL - Final result (06/15/2007 5:32 PM)

| Component | Value | Range         |
|-----------|-------|---------------|
| Sodium    | 135   | 135-148 mEq/L |
| K-Serum   | 3.9   | 3.5-5.1 mEq/L |
| Chloride  | 95    | 96-109 mEq/L  |

| Component   | Value | Range          |
|---|-------|----------------|
| Urea-Nitrogen   | 16    | 7-22 mg/dL     |
| Glucose   | 87    | 60-99 mg/dL    |
| Comment: Glucose values of 100-125 mg/dL indicate impaired fasting glucose.   |       |                |
| Creatinine, Serum.  | 1.1   | 0.6-1.3 mg/dL  |
| Calcium   | 10.2  | 8.4-10.5 mg/dL |
| Total Protein   | 7.7   | 6.0-8.2 g/dL   |
| Albumin   | 4.6   | 3.5-5.3 g/dL   |
| Total Bilirubin.  | 1.1   | 0.1-1.2 mg/dL  |
| Alanine Amino Transf  | 15    | 0-40 U/L       |
| Aspartate Amino Tran  | 23    | 0-37 U/L       |
| Alkaline Phosphatase  | 46    | 30-120 U/L     |
| CO2.  | 27    | 21-31 mEq/L    |
| Anion Gap   | 17    | 11-20 mEq/L    |
| SUN/Creatinine Ratio  | 15    |                |
| AST/ALT Ratio   | 1.5   |                |
| Est GFR Afr-Am(MDRD Eqn)  | >60   | mL/min/A       |
| Comment:<br>Estimated GFR is calculated from serum creatinine using the Modification of Diet in Renal Disease (MDRD) equation in patients 18 years or older (Am J Kidney Dis. 2002,39:524). Reference ranges:<br>>60 ml/min/A, (A=1.73 sq m). |       |                |
| Est GFR NonAfrAm(MDRD Eqn)  | >60   | mL/min/A       |
| Comment:<br>Estimated GFR is calculated from serum creatinine using the Modification of Diet in Renal Disease (MDRD) equation in patients 18 years or older (Am J Kidney Dis. 2002,39:524). Reference ranges:<br>>60 ml/min/A, (A=1.73 sq m). |       |                |

#### Narrative

Johns Hopkins Medical Labs  
Meyer B-171  
600 North Wolfe Street  
Baltimore, MD. 21287

#### APTT - Final result (11/13/2006 10:01 AM)

| Component   | Value | Range             |
|-------------|-------|-------------------|
| APTT        | 25.5  | 23.5-34.0 seconds |
| Ratio, APTT | 0.9   | PAT/NORM          |

#### Narrative

Johns Hopkins Medical Labs  
Meyer B-171  
600 North Wolfe Street  
Baltimore, MD. 21287

#### LIPID PANEL - Final result (11/13/2006 10:01 AM)

| Component            | Value | Range       |
|----------------------|-------|-------------|
| Cholesterol          | 271   | 0-200 mg/dL |
| Triglycerides        | 171   | 0-150 mg/dL |
| HDL Cholesterol.     | 52    | mg/dL       |
| LDL (Calculated).    | 185   | mg/dL       |
| Total Chol/HDL Ratio | 5.2   | Ratio       |

#### Comment:

Reference Range:  
Cholesterol  
Desirable < 200 mg/dl  
Borderline High 200-239 mg/dl  
High > 240 mg/dl  
Triglyceride  
Normal < 150 mg/dl  
Borderline High 150-199 mg/dl  
High 200-499 mg/dl  
Very High > 500 mg/dl  
HDL Cholesterol  
Undesirable < 40 mg/dl  
Desirable > 60 mg/dl  
LDL Cholesterol  
Optimal < 100 mg/dl  
Above Optimal 100-129 mg/dl  
Borderline High 130-159 mg/dl  
High 160-189 mg/dl

| Component | Value                              | Range       |
|-----------|------------------------------------|-------------|
|           | Very High                          | > 190 mg/dl |
|           | Categories of risk that modify LDL |             |
|           | Cholesterol Goals                  |             |
|           | CHD and CHR risk equivalents       | < 100 mg/dl |
|           | Multiple (2+) risk factors         | < 130 mg/dl |
|           | 0-1 risk factors                   | < 160 mg/dl |

#### Narrative

Johns Hopkins Medical Labs  
Meyer B-171  
600 North Wolfe Street  
Baltimore, MD. 21287

#### PROTHROMBIN TIME + INR (PROTIME-INR) - Final result (11/13/2006 10:01 AM)

| Component            | Value                               | Range            |
|----------------------|-------------------------------------|------------------|
| Prothrombin Time     | 9.9                                 | 9.6-11.1 seconds |
| INR, Prothrombin Tim | 1.0                                 |                  |
|                      | Comment:                            |                  |
|                      | Recommended Therapeutic INR Ranges: |                  |
|                      | Mechanical Prosthetic Heart Valves: | 2.5-3.5          |
|                      | Usual Therapeutic Range:            | 2.0-3.0          |

#### Narrative

Johns Hopkins Medical Labs  
Meyer B-171  
600 North Wolfe Street  
Baltimore, MD. 21287

#### COMPREHENSIVE METABOLIC PANEL - Final result (11/13/2006 10:01 AM)

| Component                  | Value  | Range          |
|----------------------------|--|----------------|
| Sodium                     | 143  | 135-148 mEq/L  |
| K-Serum                    | 4.0  | 3.5-5.0 mEq/L  |
| Chloride                   | 105  | 96-109 mEq/L   |
| Urea-Nitrogen              | 13   | 7-22 mg/dL     |
| Glucose                    | 99   | 60-99 mg/dL    |
|                            | Comment: Glucose values of 100-125 mg/dL indicate impaired fasting glucose.  |                |
| Creatinine, Serum.         | 1.0  | 0.6-1.3 mg/dL  |
| Calcium                    | 9.9  | 8.4-10.5 mg/dL |
| Total Protein              | 7.6  | 6.0-8.2 g/dL   |
| Albumin                    | 4.3  | 3.5-5.3 g/dL   |
| Total Bilirubin.           | 0.5  | 0.1-1.2 mg/dL  |
| Alanine Amino Transf       | 12   | 0-40 U/L       |
| Aspartate Amino Tran       | 21   | 0-37 U/L       |
| Alkaline Phosphatase       | 46   | 30-120 U/L     |
| CO2.                       | 30   | 21-31 mEq/L    |
| Anion Gap                  | 12   | 11-20 mEq/L    |
| SUN/Creatinine Ratio       | 13   |                |
| AST/ALT Ratio              | 1.8  |                |
| Est GFR Afr-Am(MDRD Eqn)   | >60  | mL/min/A       |
|                            | Comment:   |                |
|                            | Estimated GFR is calculated from serum creatinine using the Modification of Diet in Renal Disease (MDRD) equation in patients 18 years or older (Am J Kidney Dis. 2002,39:524). Reference ranges: >60 ml/min/A, (A=1.73 sq m). |                |
| Est GFR NonAfrAm(MDRD Eqn) | >60  | mL/min/A       |
|                            | Comment:   |                |
|                            | Estimated GFR is calculated from serum creatinine using the Modification of Diet in Renal Disease (MDRD) equation in patients 18 years or older (Am J Kidney Dis. 2002,39:524). Reference ranges: >60 ml/min/A, (A=1.73 sq m). |                |

#### Narrative

Johns Hopkins Medical Labs  
Meyer B-171  
600 North Wolfe Street  
Baltimore, MD. 21287

#### COMPLETE BLOOD COUNT (CBC) WITHOUT DIFFERENTIAL (CBC) - Final result (11/13/2006 10:01 AM)

| Component              | Value | Range             |
|------------------------|-------|-------------------|
| White Blood Cell Count | 5370  | 4500-11000 /cu mm |



| Component               | Value | Range             |
|-------------------------|-------|-------------------|
| Red Blood Cell Count    | 4.56  | 4.50-5.90 M/cu mm |
| Hemoglobin              | 13.4  | 13.9-16.3 g/dL    |
| Hematocrit              | 39.2  | 41.0-53.0 %       |
| Mean Corpuscular Volume | 86.0  | 80.0-100.0 fL     |
| Mean Corpus Hgb         | 29.4  | 26.0-34.0 pg      |
| Mean Corpus Hgb Conc    | 34.2  | 31.0-37.0 g/dL    |
| RBC Distribution Width  | 12.8  | 11.5-14.5 %       |
| Platelet Count          | 268   | 150-350 K/cu mm   |
| Mean Platelet Volume    | 10.1  | 9.2-12.7 fL       |
| Nucleated RBC Number    | 0     | 0-12 /cu mm       |

**Narrative**

Johns Hopkins Medical Labs  
Meyer B-171  
600 North Wolfe Street  
Baltimore, MD. 21287

**ECG 12-LEAD (EKG 12-LEAD) - Final result (11/13/2006 9:40 AM)**

**Narrative**

```

THE          *      HISTORY NO. : 001636284
JOHNS HOPKINS *      NAME: ANDREW, CLIFFORD
HOSPITAL     *      AGE/ RACE/ SEX: 60 Years   WHITE       MALE
              *      LOCATION: OTHCL
              *      REFERRED BY:
ELECTROCARDIOGRAM *      ATTENDING M.D.:
REPORT        *      DATE / TIME: 11/13/06 @ 09:40

```

=====

INDICATION FOR STUDY: N/A

|                  |     |         |
|------------------|-----|---------|
| Ventricular Rate | 56  | BPM     |
| Atrial Rate      | 56  | BPM     |
| P-R Interval     | 160 | ms      |
| QRS Duration     | 96  | ms      |
| QT Interval      | 422 | ms      |
| QTc Interval     | 407 | ms      |
| P Axis           | 71  | degrees |
| R Axis           | 23  | degrees |
| T Axis           | 52  | degrees |

SINUS BRADYCARDIA  
OTHERWISE NORMAL ECG

GC: N

Confirmed by: CHARLES HENRIKSON, M.D.

Technician: TC

Note: This note provides information pertaining only to a specific event. A more detailed medical history is available in the Medical Record.

**URINALYSIS (URINALYSIS AUTO W/SCOPE) - Final result (08/25/2006 3:03 PM)**

| Component                   | Value      | Range   |
|-----------------------------|------------|---|
| Specific Gravity, Urine     | 1.026      | 1.003-1.030   |
| Appearance, Urine           | CLEAR      |   |
| Color, Urine                | YELLOW     |   |
| Glucose, Urine, Semiquant   | Neg        |   |
| Bilirubin Qualitative       | NEG        |   |
| Ketones, Urine, Qualitative | TR         |   |
| Blood, Urine                | NEG        |   |
| Urine pH                    | 6.0        | 4.6-8.0   |
| Protein Semiquant, UA       | NEG        |   |
| Leukocyte Esterase, Urine   | NEG        |   |
| Nitrite, Urine              | NEGATIVE   |   |
| Mucus Threads, Urine        | OCCASIONAL | Comment: Reference range: None to few/lpf #/lpf   |
| Hyaline Casts, Urine        | 0          | Comment: Reference range: 0-1 per lpf #/lpf   |
| Granular Casts, Urine       | 0          | Comment: Reference range: None present #/lpf  |
| Red Blood Cells, Urine      | 1          | Comment: Reference range: 0-5 per hpf #/hpf   |
| Red Blood Cells, UA         | 8          | 0-27 /microlite   |
| White Blood Cells, Urine    | 1          | Comment: Reference range: 0-5 per hpf #/hpf   |
| White Blood Cells, UA       | 5          | 0-27 /microlite   |
| Epithelial Cells, Urine     | 0          | Comment: #/hpf<br>Any number of squamous epithelial cells is normal. The presence of either renal or transitional epithelial cells is abnormal. |
| Bacteria, Urine             | RARE       | Comment: Reference range: None to few/hpf /hpf  |

**Narrative**

Johns Hopkins Medical Labs

**Narrative**

Meyer B-171  
 600 North Wolfe Street  
 Baltimore, MD. 21287

**PSA, TOTAL (PSA) - Final result (08/25/2006 2:59 PM)**

| Component  | Value | Range         |
|--|-------|---------------|
| Prostate Spec Ag-Tosoh   | 2.6   | 0.0-4.0 ng/mL |
| <b>Comment:</b><br>The presence of human anti-mouse antibodies (HAMA), which can result from mouse monoclonal antibodies used for diagnosis or therapy, or heterophile antibodies may cause an interference in this assay. |       |               |

**Narrative**

Johns Hopkins Medical Labs  
 Meyer B-154  
 600 North Wolfe Street  
 Baltimore, MD. 21287

**COMPLETE BLOOD COUNT (CBC) WITHOUT DIFFERENTIAL (CBC) - Final result (08/25/2006 2:59 PM)**

| Component               | Value | Range             |
|-------------------------|-------|-------------------|
| White Blood Cell Count  | 5480  | 4500-11000 /cu mm |
| Red Blood Cell Count    | 4.47  | 4.50-5.90 M/cu mm |
| Hemoglobin              | 12.9  | 13.9-16.3 g/dL    |
| Hematocrit              | 38.4  | 41.0-53.0 %       |
| Mean Corpuscular Volume | 85.9  | 80.0-100.0 fL     |
| Mean Corpus HgB         | 28.9  | 26.0-34.0 pg      |
| Mean Corpus HgB Conc    | 33.6  | 31.0-37.0 g/dL    |
| RBC Distribution Width  | 12.8  | 11.5-14.5 %       |
| Platelet Count          | 259   | 150-350 K/cu mm   |
| Mean Platelet Volume    | 10.2  | 9.2-12.7 fL       |
| Nucleated RBC Number    | 0     | 0-12 /cu mm       |

**Narrative**

Johns Hopkins Medical Labs  
 Meyer B-171  
 600 North Wolfe Street  
 Baltimore, MD. 21287

**C-REACTIVE PROTEIN - Final result (08/25/2006 2:59 PM)**

| Component | Value                                     | Range         |
|-----------|---|---------------|
| CRP       | 0.3 <b>Comment: RESULT DOUBLE CHECKED</b> | 0.0-0.5 mg/dL |

**Narrative**

Johns Hopkins Medical Labs  
 Meyer B-171  
 600 North Wolfe Street  
 Baltimore, MD. 21287

**LIPID PANEL - Final result (08/25/2006 2:59 PM)**

| Component            | Value | Range       |
|----------------------|-------|-------------|
| Cholesterol          | 270   | 0-200 mg/dL |
| Triglycerides        | 100   | 0-150 mg/dL |
| HDL Cholesterol      | 50    | mg/dL       |
| LDL (Calculated)     | 200   | mg/dL       |
| Total Chol/HDL Ratio | 5.4   | Ratio       |

**Comment:**

**Reference Range:**

|                        |               |
|------------------------|---------------|
| <b>Cholesterol</b>     |               |
| Desirable              | < 200 mg/dl   |
| Borderline High        | 200-239 mg/dl |
| High                   | > 240 mg/dl   |
| <b>Triglyceride</b>    |               |
| Normal                 | < 150 mg/dl   |
| Borderline High        | 150-199 mg/dl |
| High                   | 200-499 mg/dl |
| Very High              | > 500 mg/dl   |
| <b>HDL Cholesterol</b> |               |
| Undesirable            | < 40 mg/dl    |
| Desirable              | > 60 mg/dl    |
| <b>LDL Cholesterol</b> |               |
| Optimal                | < 100 mg/dl   |
| Above Optimal          | 100-129 md/dl |
| Borderline High        | 130-159 md/dl |
| High                   | 160-189 mg/dl |
| Very High              | > 190 mg/dl   |

Categories of risk that modify LDL Cholesterol Goals

| Component | Value                        | Range       |
|-----------|------------------------------|-------------|
|           | CHD and CHR risk equivalents | < 100 mg/dl |
|           | Multiple (2+) risk factors   | < 130 mg/dl |
|           | 0-1 risk factors             | < 160 mg/dl |

#### Narrative

Johns Hopkins Medical Labs  
Meyer B-171  
600 North Wolfe Street  
Baltimore, MD. 21287

#### COMPREHENSIVE METABOLIC PANEL - Final result (08/25/2006 2:59 PM)

| Component                  | Value  | Range          |
|----------------------------|--|----------------|
| Sodium                     | 139  | 135-148 mEq/L  |
| K-Serum                    | 3.9  | 3.5-5.0 mEq/L  |
| Chloride                   | 101  | 96-109 mEq/L   |
| Urea-Nitrogen              | 14   | 7-22 mg/dL     |
| Glucose                    | 92   | 60-99 mg/dL    |
|                            | Comment: Glucose values of 100-125 mg/dL indicate impaired fasting glucose.  |                |
| Creatinine, Serum.         | 1.1  | 0.6-1.3 mg/dL  |
| Calcium                    | 10.1   | 8.4-10.5 mg/dL |
| Total Protein              | 7.6  | 6.0-8.2 g/dL   |
| Albumin                    | 4.4  | 3.5-5.3 g/dL   |
| Total Bilirubin.           | 0.8  | 0.1-1.2 mg/dL  |
| Alanine Amino Transf       | 13   | 0-40 U/L       |
| Aspartate Amino Tran       | 23   | 0-37 U/L       |
| Alkaline Phosphatase       | 43   | 30-120 U/L     |
| CO2.                       | 26   | 21-31 mEq/L    |
| Anion Gap                  | 16   | 11-20 mEq/L    |
| SUN/Creatinine Ratio       | 13   |                |
| AST/ALT Ratio              | 1.8  |                |
| Est GFR Afr-Am(MDRD Eqn)   | >60  | mL/min/A       |
|                            | Comment:<br>Estimated GFR is calculated from serum creatinine using the Modification of Diet in Renal Disease (MDRD) equation in patients 18 years or older (Am J Kidney Dis. 2002,39:524). Reference ranges: >60 ml/min/A, (A=1.73 sq m). |                |
| Est GFR NonAfrAm(MDRD Eqn) | >60  | mL/min/A       |
|                            | Comment:<br>Estimated GFR is calculated from serum creatinine using the Modification of Diet in Renal Disease (MDRD) equation in patients 18 years or older (Am J Kidney Dis. 2002,39:524). Reference ranges: >60 ml/min/A, (A=1.73 sq m). |                |

#### Narrative

Johns Hopkins Medical Labs  
Meyer B-171  
600 North Wolfe Street  
Baltimore, MD. 21287

#### XR CHEST PA AND LATERAL - Final result (08/25/2006)

#### Narrative

The Russell H. Morgan Department Of Radiology  
and Radiological Science  
The Johns Hopkins Hospital, Baltimore MD. 21287

ANDREW, CLIFFORD

Exam Date: 08/25/2006 14:36 ORD #90001 Accession #4790303  
History Number: 1636284  
Age: 59Y Sex: M Race: W  
Requester: DANIEL E FORD M.D.

EXAM: DGJ 1010 - CHEST PA AND LATERAL - Aug 25, 2006 14:36  
ACC:4790303

#### RESULT:

CHEST PA AND LATERAL: 2 VIEWS: 8/25/2006 14:36:00

INDICATION: Positive PPD, pre-employment evaluation.

Small calcified granuloma left upper lobe.

**Narrative**

Normal cardiovascular structures.  
CTR 11/33.

Schmor's nodes inferior endplates T10 and T11 with surrounding sclerosis,  
with no current clinical significance.

**IMPRESSION:**

..:Updated Aug 25 2006 4:57P---

OLGA M.B. GATEWOOD M.D.

**IMAGES AND INTERPRETATION PERSONALLY READ BY:**

OLGA M.B. GATEWOOD M.D.

**PROTHROMBIN TIME + INR (PROTIME-INR) - Final result (10/20/2005 2:50 PM)**

| Component                           | Value | Range            |
|-------------------------------------|-------|------------------|
| Prothrombin Time                    | 10.4  | 9.7-11.3 seconds |
| INR, Prothrombin Tim                | 1.0   |                  |
| Comment:                            |       |                  |
| Recommended Therapeutic INR Ranges: |       |                  |
| Mechanical Prosthetic Heart Valves: | 2.5-  |                  |
|                                     | 3.5   |                  |
| Usual Therapeutic Range:            | 2.0-  |                  |
|                                     | 3.0   |                  |

**APTT - Final result (10/20/2005 2:50 PM)**

| Component   | Value | Range             |
|-------------|-------|-------------------|
| APTT        | 25.5  | 23.5-34.0 seconds |
| Ratio, APTT | 0.9   | PAT/NORM          |

**COMPLETE BLOOD COUNT (CBC) WITHOUT DIFFERENTIAL (CBC) - Final result (10/20/2005 2:50 PM)**

| Component               | Value | Range             |
|-------------------------|-------|-------------------|
| White Blood Cell Count  | 6750  | 4500-11000 /cu mm |
| Red Blood Cell Count    | 4.69  | 4.50-5.90 M/cu mm |
| Hemoglobin              | 13.9  | 13.9-16.3 g/dL    |
| Hematocrit              | 40.8  | 41.0-53.0 %       |
| Mean Corpuscular Volume | 87.0  | 80.0-100.0 fL     |
| Mean Corpus HgB         | 29.6  | 26.0-34.0 pg      |
| Mean Corpus HgB Conc    | 34.1  | 31.0-37.0 g/dL    |
| RBC Distribution Width  | 12.9  | 11.5-14.5 %       |
| Platelet Count          | 279   | 150-350 K/cu mm   |
| Mean Platelet Volume    | 9.9   | 9.2-12.7 fL       |
| Nucleated RBC Number    | 0     | 0-12 /cu mm       |

**LIPID PANEL - Final result (10/13/2005 7:26 AM)**

| Component            | Value | Range       |
|----------------------|-------|-------------|
| Cholesterol          | 209   | 0-200 mg/dL |
| Triglycerides        | 102   | 0-150 mg/dL |
| HDL Cholesterol      | 62    | mg/dL       |
| LDL (Calculated)     | 127   | mg/dL       |
| Total Chol/HDL Ratio | 3.4   | Ratio       |

**Comment:**

**Reference Range:**

**Cholesterol**

Desirable < 200 mg/dl  
Borderline High 200-239 mg/dl  
High > 240 mg/dl

**Triglyceride**

Normal < 150 mg/dl  
Borderline High 150-199 mg/dl  
High 200-499 mg/dl  
Very High > 500 mg/dl

**HDL Cholesterol**

Undesirable < 40 mg/dl  
Desirable > 60 mg/dl

**LDL Cholesterol**

Optimal < 100 mg/dl  
Above Optimal 100-129 md/dl  
Borderline High 130-159 md/dl  
High 160-189 mg/dl  
Very High > 190 mg/dl

**Categories of risk that modify LDL**

**Cholesterol Goals**

CHD and CHR risk equivalents < 100 mg/dl  
Multiple (2+) risk factors < 130 mg/dl

| Component | Value            | Range       |
|-----------|------------------|-------------|
|           | 0-1 risk factors | < 160 mg/dl |

**PSA, TOTAL (PSA) - Final result (10/13/2005 7:26 AM)**

| Component   | Value | Range         |
|---|-------|---------------|
| Prostate Spec Ag-Tosoh  | 1.9   | 0.0-4.0 ng/mL |
| Comment:<br>The presence of human anti-mouse antibodies (HAMA), which can result from mouse monoclonal antibodies used for diagnosis or therapy, or heterophile antibodies may cause an interference in this assay. |       |               |

**RENAL FUNCTION PANEL - Final result (10/13/2005 7:26 AM)**

| Component            | Value | Range          |
|----------------------|-------|----------------|
| Sodium               | 136   | 135-148 mEq/L  |
| K-Serum              | 4.4   | 3.5-5.0 mEq/L  |
| Chloride             | 98    | 96-109 mEq/L   |
| CO2                  | 31    | 21-31 mEq/L    |
| Urea-Nitrogen        | 19    | 7-22 mg/dL     |
| Glucose              | 120   | 60-109 mg/dL   |
| Creatinine, Serum.   | 0.9   | 0.6-1.3 mg/dL  |
| Albumin              | 4.4   | 3.5-5.3 g/dL   |
| Calcium              | 10.3  | 8.4-10.5 mg/dL |
| Phosphorus           | 3.4   | 2.7-4.5 mg/dL  |
| Anion Gap            | 11    | 11-20 mEq/L    |
| SUN/Creatinine Ratio | 21    |                |

**SURGICAL PATHOLOGY REPORTN (SURGICAL PATHOLOGY REPORT) - Final result (11/18/2004)**

| Component            | Value | Range |
|----------------------|-------|-------|
| Surgical Pathology R |       |       |

THE Patient: ANDREW MD,CLIFFORD Path# S04-63426  
 JOHNS HOPKINS HOSPITAL JHH MR # 5-163-62-84 Accessioned  
 11/18/2004  
 SURGICAL Birthdate: 09/10/1946 (Age 58) Loc: 319CL  
 PATHOLOGY  
 401 N. Broadway Gender: M Spec. Taken  
 11/18/2004  
 Baltimore, Md.  
 21231-2410 JHH Physician: FRANCIS D MILLIGAN,  
 M.D.  
 =====

INTERPRETATION AND DIAGNOSIS: (jxs) 11/22/2004 @ 11:30 am

COLON (BIOPSY OF DESCENDING COLON): TUBULAR ADENOMA.

Elizabeth Montgomery, M.D. EM\*

\*Electronic signature (11/22/2004 @ 03:41 pm) by which I attest that the above diagnosis is based upon my personal examination of the slides (and / or other material indicated in the diagnosis), and that I have reviewed and approved this report.

Clinical History:  
 R/O POLYPS

GROSS DESCRIPTION

PART #1: DESCENDING COLON POLYP (kmq)  
 Resident Pathologist: HAYAN JARATLI, M.D. 11/18/2004

The specimen is received in formalin labeled with the patient's name Andrew, Clifford and designated descending colon polyp. It consists of 1 piece of tissue measuring 0.4 x 0.2 x 0.2 cm. The specimen is submitted to the lab in its entirety.

SUMMARY OF SECTIONS  
 1 - A - 1  
 1 - TOTAL - 1

(End of Report)  
16:25

printed 09/05/2012

### Narrative

The Johns Hopkins Hospital, Surgical Pathology  
401 N. Broadway, Baltimore, MD 21231  
Tel: 410-955-3580

### ECG 12-LEAD - Final result (10/14/2004 4:10 PM)

#### Narrative

THE \* HISTORY NO.: 1636284  
JOHNS HOPKINS \* NAME: ANDREW, CLIFFORD  
HOSPITAL \* AGE / RACE SEX: 58 YR OLD WHITE MALE  
\* LOCATION: CL107  
\* REFERRED BY:  
ELECTROCARDIOGRAM \* ATTENDING M.D.:  
REPORT \* DATE / TIME: 10/14/04 @ 16:10

INDICATION FOR STUDY: routine

|                  |     |         |
|------------------|-----|---------|
| Ventricular Rate | 46  | BPM     |
| Atrial Rate      | 46  | BPM     |
| P-R Interval     | 156 | ms      |
| QRS Duration     | 98  | ms      |
| QT Interval      | 452 | ms      |
| QTc Interval     | 395 | ms      |
| P Axis           | 63  | degrees |
| R Axis           | 21  | degrees |
| T Axis           | 44  | degrees |

MARKED SINUS BRADYCARDIA WITH SINUS ARRHYTHMIA  
INCOMPLETE RIGHT BUNDLE BRANCH BLOCK  
ABNORMAL ECG

Interpreting M.D.: C.Lowenstein #: 62091  
GC: N

Confirmed by: CHARLES LOWENSTEIN, M.D.

Technician: tmcfail

Note: This note provides information pertaining only to a specific event. A more detailed medical history is available in the Medical Record.

### URINALYSIS (URINALYSIS WITH MICROSCOPIC REFLEX) - Final result (10/14/2004 4:03 PM)

| Component                   | Value    | Range       |
|-----------------------------|----------|-------------|
| Specific Gravity, Urine     | 1.008    | 1.003-1.030 |
| Appearance, Urine           | CLEAR    |             |
| Color, Urine                | YELLOW   |             |
| Glucose, Urine, Semiquant   | Neg      |             |
| Bilirubin Qualitative       | NEG      |             |
| Ketones, Urine, Qualitative | NEG      |             |
| Blood, Urine                | NEG      |             |
| Urine pH                    | 7.0      | 4.6-8.0     |
| Protein Semiquant, UA       | NEG      |             |
| Leukocyte Esterase, Urine   | NEG      |             |
| Nitrite, Urine              | NEGATIVE |             |
| Mucus Threads, Urine        | NONE     | #/lpf       |
| Hyaline Casts, Urine        | NONE     | #/lpf       |
| Granular Casts, Urine       | NONE     | #/lpf       |
| Red Blood Cells, Urine      | NONE     | #/hpf       |
| White Blood Cells, Urine    | NONE     | #/hpf       |
| Epithelial Cells, Urine     | NONE     | #/hpf       |
| Bacteria, Urine             | NONE     | /hpf        |
| Crystals                    | NONE     | #/HPF       |
| Other Cells Urine           | NONE     | #/HPF       |

### COMPREHENSIVE METABOLIC PANEL - Final result (10/14/2004 4:00 PM)

| Component          | Value | Range          |
|--------------------|-------|----------------|
| Sodium             | 138   | 135-148 mEq/L  |
| K-Serum            | 4.3   | 3.5-5.0 mEq/L  |
| Chloride           | 101   | 96-109 mEq/L   |
| Urea-Nitrogen      | 16    | 7-22 mg/dL     |
| Glucose            | 90    | 60-109 mg/dL   |
| Creatinine, Serum. | 0.9   | 0.6-1.3 mg/dL  |
| Calcium            | 10.0  | 8.4-10.5 mg/dL |
| Total Protein      | 7.7   | 6.0-8.2 g/dL   |
| Albumin            | 4.5   | 3.5-5.3 g/dL   |
| Total Bilirubin.   | 1.0   | 0.1-1.2 mg/dL  |

| Component            | Value | Range       |
|----------------------|-------|-------------|
| Alanine Amino Transf | 16    | 0-40 U/L    |
| Aspartate Amino Tran | 18    | 0-37 U/L    |
| Alkaline Phosphatase | 51    | 30-120 U/L  |
| CO2.                 | 31    | 21-31 mEq/L |
| Anion Gap            | 10    | 11-20 mEq/L |
| SUN/Creatinine Ratio | 18    |             |

**PSA, TOTAL (PSA) - Final result (10/14/2004 4:00 PM)**

| Component              | Value | Range         |
|------------------------|-------|---------------|
| Prostate Spec Ag-Tosoh | 1.8   | 0.0-4.0 ng/mL |

**Comment:**

Post Prostatectomy Less Than 0.2 ng/ml  
 .  
 The presence of human anti-mouse antibodies (HAMA), which can result from mouse monoclonal antibodies used for diagnosis or therapy, or heterophile antibodies may cause an interference in this assay.

**FERRITIN - Final result (10/14/2004 4:00 PM)**

| Component | Value | Range        |
|-----------|-------|--------------|
| Ferritin  | 145   | 10-300 ng/mL |

**IRON, TIBC,% TRANSFERRIN SATURATION (TRANSFERRIN+IRON(TIBC),SERUM) - Final result (10/14/2004 4:00 PM)**

| Component            | Value | Range         |
|----------------------|-------|---------------|
| Iron,Serum           | 73    | 65-170 mcg/dL |
| Transferrin,Serum    | 256   | 200-400 mg/dL |
| Total Iron Binding C | 320   | 250-450 mg/dL |
| Percent Saturation   | 23    | 20-55 %       |

**LIPID PANEL - Final result (10/14/2004 4:00 PM)**

| Component            | Value | Range       |
|----------------------|-------|-------------|
| Cholesterol          | 266   | 0-200 mg/dL |
| Triglycerides        | 110   | 0-150 mg/dL |
| HDL Cholesterol.     | 46    | mg/dL       |
| LDL (Calculated).    | 198   | mg/dL       |
| Total Chol/HDL Ratio | 5.8   | Ratio       |

**Comment:**

Reference Range:  
 Cholesterol  
 Desirable < 200 mg/dl  
 Borderline High 200-239 mg/dl  
 High > 240 mg/dl  
 Triglyceride  
 Normal < 150 mg/dl  
 Borderline High 150-199 mg/dl  
 High 200-499 mg/dl  
 Very High > 500 mg/dl  
 HDL Cholesterol  
 Undesirable < 40 mg/dl  
 Desirable > 60 mg/dl  
 LDL Cholesterol  
 Optimal < 100 mg/dl  
 Above Optimal 100-129 md/dl  
 Borderline High 130-159 md/dl  
 High 160-189 mg/dl  
 Very High > 190 mg/dl  
 Categories of risk that modify LDL  
 Cholesterol Goals  
 CHD and CHR risk equivalents < 100 mg/dl  
 Multiple (2+) risk factors < 130 mg/dl  
 0-1 risk factors < 160 mg/dl

**APTT - Final result (10/14/2004 4:00 PM)**

| Component   | Value | Range             |
|-------------|-------|-------------------|
| APTT        | 27.1  | 23.5-34.0 seconds |
| Ratio, APTT | 0.9   | PAT/NORM          |

**PROTHROMBIN TIME + INR (PROTHROMBIN TIME) - Final result (10/14/2004 4:00 PM)**

| Component            | Value | Range            |
|----------------------|-------|------------------|
| Prothrombin Time     | 10.9  | 9.5-11.7 seconds |
| INR, Prothrombin Tim | 1.0   |                  |

**Comment:**

Recommended Therapeutic INR Ranges:  
 Mechanical Prosthetic Heart Valves: 2.5-3.5  
 Usual Therapeutic Range: 2.0-3.0

**COMPLETE BLOOD COUNT (CBC) WITHOUT DIFFERENTIAL (COMPLETE BLOOD COUNT (CBC)) - Final result (10/14/2004 4:00 PM)**

| Component               | Value | Range   |
|-------------------------|-------|---|
| White Blood Cell Count  | 8410  | 4500-11000 /cu mm   |
| Red Blood Cell Count    | 4.63  | 4.50-5.90 M/cu mm   |
| Hemoglobin              | 13.5  | 13.9-16.3 g/dL  |
| Hematocrit              | 39.8  | 41.0-53.0 %   |
| Mean Corpuscular Volume | 86.0  | 80.0-100.0 fL   |
| Mean Corpus HgB         | 29.2  | 26.0-34.0 pg  |
| Mean Corpus HgB Conc    | 33.9  | 31.0-37.0 g/dL  |
| RBC Distribution Width  | 12.8  | 11.5-14.5 %   |
| Platelet Count          | 320   | 150-350 K/cu mm   |
| Mean Platelet Volume    | 9.7   | 9.2-12.7 fL   |
| Nucleated RBC Number    | 0     | Comment: Value is the number of NRBC's per cu mm of blood 0-12 /cu mm |



If you take your Lucy record on a thumb drive to a different doctor, he or she might be able to use his computer to read the file electronically. Your downloaded, machine-readable Personal Health Summary document is in a format called "CDA." If your doctor has a computer that understands CDA, your information is a folder on your thumb drive called **MachineReadable\_XDMFormat**. You might need to enter a password before your doctor can use this file.

Copyright ©2016 Epic